Identifying transplanted cells in the context of regenerative medicine for stroke by Nicholls, Francesca Joan
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 



















IDENTIFYING TRANSPLANTED CELLS IN THE 










Institute of Psychiatry, King’s College London 
 








Exogenous labels are often used to identify transplanted cells in order to elucidate their 
therapeutic mechanisms. In the context of stem and progenitor cell transplants, the requirements 
for exogenous labels must be ever more stringent in order to avoid both short and long term 
effects on the biology of these sensitive cell types, as well as to ensure accurate identification of 
transplanted cells. As cell therapies become more complex, there is also a need to be able to 
simultaneously image different cell populations in vivo. 
Here four commonly used “optical” labeling protocols (Hoechst, BrdU, PKH26 and Qtracker) and 
an MRI contrast agent (a new Gadolinium nanoparticle based on ProHance) are assessed for 
their effects on human neural stem cell (hNSC) biology and their sensitivity and reliability for 
identification of transplanted cells.  
With a view to developing useful paradigms for in vivo imaging of tissue engineering, two 
ParaCEST (Paramagnetic Chemical Exchange Saturation Transfer) agents are used to label 
hNSCs and human brain microvascular endothelial cells. MRI is then used to image each cell 
population separately after transplantation into the stroke cavity in a rat MCAO (middle cerebral 
artery occlusion) model. 
These studies will allow the selection of labels that will have minimal effects on NSC biology 
whilst retaining maximal label reliability, and thereby allow accurate elucidation of the effects of 
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Chapter 1: Introduction   . 
1.1 Stroke pathophysiology and treatment 
Stroke is the third leading global cause of loss of Disability Adjusted Life Years (DALYs), with 572 
DALYs lost per 100,000 in 2010 (Murray, Vos et al. 2012). The annual societal cost is estimated 
at £8.9 billion in the UK alone (Saka, McGuire et al. 2009). The only acute treatment currently 
available for stroke is tissue plasminogen activator (t-PA), which is used to break down thrombi 
and restore blood flow. However, only 14% of a sample of 11,262 stroke cases in the UK were 
eligible for t-PA, with the majority of exclusions due to the effective time window of three hours 
(Rudd, Hoffman et al. 2011). For the majority of stroke sufferers, there is no available intervention. 
Their vascular conditions can be appropriately treated to reduce the probability of another attack, 
but the only intervention to reduce symptoms resulting from damaged brain tissue is rehabilitation 
therapy. Rehabilitation is highly effective in improving functional outcome (Cifu and Stewart), but 
many patients still suffer from significant long-lasting disability. There is therefore an urgent need 
for therapies that can be applied in a broader time window and facilitate functional recovery to 
restore quality of life.  
Ischemic stroke occurs when the occlusion of a blood vessel disrupts blood flow to an area of the 
brain. The reduction in oxygen and glucose first causes cells to lose function, starting with a loss 
of electrical activity in neurons. As the duration of ischemia extends beyond 30 minutes, cells 
begin to die after failure of vital functions such as membrane ion pumps (Bell, Symon et al. 1985, 
Lipton 1999). This results in a core of dead tissue surrounded by cells having lost their electrical 
activity but not yet their other functions, dubbed the penumbra. The extent and duration of 
penumbral tissue is highly variable between individuals, but can be found up to 16 hours after 
stroke onset (Marchal, Beaudouin et al. 1996). 
This presents a number of therapeutic opportunities. Reperfusion allows prevention of further 
damage to the outer area, and preservation of penumbral tissue integrity, while neuroprotective 
therapies are aimed at preventing neuronal cell death within the penumbra. However the only 




Figure 1.1 Time course of damage and potential interventions in ischemic stroke. The blue area represents 
“at risk” tissue, salvageable by reperfusion; purple represent the penumbra, the target of neuroprotective 
therapies; and red represents the core of the lesion and focus of cell replacement therapy. The numbers on 
the left represent approximate cerebral blood flow in ml/100g/min based on Moustafa and Baron (2008). 
 
In adult humans, the central nervous system (CNS) has the most limited capacity for self-repair, 
and is well behind other tissues in its ability to recover from injury. However, there are a number 
of endogenous repair mechanisms initiated in response to stroke that underlie natural recovery. 
Neurogenesis, angiogenesis, and axonal sprouting collectively bring about a degree of repair and 
functional recovery after stroke.  
Neurogenesis occurs in the subventricular zone (SVZ) of the lateral ventricle throughout the life of 
adult mammals (Alvarez-Buylla, Herrera et al. 2000). It is transiently upregulated from two days 
after middle cerebral artery occlusion (MCAO) in adult rats and persists for two weeks, reaching a 
maximum at 4-7 days (Zhang, Zhang et al. 2008). These cells have been shown to migrate to the 
ischemic boundary and express markers of developing and mature neurons (Arvidsson, Collin et 
al. 2002). Upregulation of neurogenesis after stroke has also been shown in elderly human stroke 
patients (Minger, Ekonomou et al. 2007). This appears to be coupled to angiogenesis (Leventhal, 
Rafii et al. 1999). Endothelial cell proliferation all but ceases under healthy conditions, with a 
turnover rate of approximately three years in the adult rodent brain (Robertson, Du Bois et al. 
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1985). However, angiogenesis is upregulated after stroke, with higher blood vessel counts 
correlating with longer patient survival (Krupinski, Kaluza et al. 1994). Endothelial cells 
additionally provide factors that stimulate self-renewal of neural stem cells (Shen, Goderie et al. 
2004), and neuroblasts  have been shown to migrate along blood vessels  (Thored, Wood et al. 
2007). 
In traumatic CNS injuries, expression of proteins associated with inhibition of axonal growth is 
upregulated (Hunt, Coffin et al. 2003), creating an environment that is non-permissive for 
neuronal growth. However, in stroke the glial scar forms in the region of high apoptotic cell death 
closely bordering the infarct, which contains both inhibitory and growth-promoting molecules. But 
there is also a large region of peri-infarct tissue that has high levels of growth-promoting 
molecules and low levels of inhibitory molecules (Carmichael, Archibeque et al. 2005). It is in this 
area that a high axonal sprouting response is observed (Carmichael, Wei et al. 2001, Li, Overman 
et al. 2010). 
Knowledge of the pathophysiology of stroke and its endogenous repair mechanisms has 
presented researchers with two main therapeutic strategies. The first is to supply drugs to target 
ongoing processes, such as promoting angiogenesis or preventing apoptosis in the penumbra. 
The second is to deliver cells, which may both supply a cocktail of growth factors to damaged 
tissue and serve as potential replacements for lost cells. 
1.1.1 Drug delivery and biomaterials 
Drug delivery targets ongoing processes, aiming either to prevent those that are thought to be 
detrimental, or enhance endogenous repair mechanisms. 
Excitotoxicity can be attenuated using the NMDA (N-methyl-D-aspartate) antagonist memantine, 
which has been shown to improve behavioural outcome (Liu, Lin et al. 2009, Lopez-Valdes, 
Clarkson et al. 2014). There are many growth factors that are thought to enhance stroke recovery 
through a variety of mechanisms. Vascular endothelial growth factor (VEGF) is known to increase 
angiogenesis (Zhang, Zhang et al. 2000), Basic fibroblast growth factor (bFGF/FGF2) stimulates 
growth and proliferation of endothelial cells (Sahni, Sporn et al. 1999), and glial-derived 
neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) have shown strong 
neuroprotective effects (Kurozumi, Nakamura et al. 2005). Stromal cell-derived factor 1 (SDF-1) is 
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a chemo attractant and attracts immune elements and progenitor cells (Fan, Shen et al. 2010), 
and thrombospondin has been shown to mediate synaptogenesis (Liauw, Hoang et al. 2008). 
However, most compounds delivered systemically suffer from a poor BBB penetration, 
compounds being quickly metabolized, and potential significant side-effects due to drugs affecting 
other organ systems (Dirnagl 2006, Ciofani, Raffa et al. 2008). Therefore many groups have 
looked into combination with biomaterials for delivery. Studies have shown that some growth 
factors are more effective when anchored to a biomaterial than when available in solution. Sahni 
et al. (1999) found higher proliferation of endothelial cells in the presence of bFGF attached to 
fibrinogen than in the presence of bFGF in solution. Intra-ventricular delivery of Nerve growth 
factor (NGF) within liposomes was shown to provide significantly higher tissue concentration of 
NGF then when delivered as a solution (Luk, Chen et al. 2004). NGF was also shown to have a 
larger effect on axon elongation in vitro when anchored to poly(dimethyl siloxane) (PDMS) than in 
solution (Gomez, Lu et al. 2007). Superoxide dismutase, a free radical scavenger, can be 
incorporated into biodegradable poly(D,L-lactide-co-glycolide) nanoparticles and achieve a 65% 
reduction in lesion volume, whereas the same dose in solution only achieved a 25% decrease 
(Reddy and Labhasetwar 2009). 
It therefore seems that biomaterials play a vital role here. The chemistry behind release profiles of 
different biomaterials is now very advanced, and the time course of release can be carefully 
controlled in vitro (White, Kirby et al. 2013). However, this release may be much more difficult to 
control in a poorly characterized environment. Although in vitro efforts are in progress to establish 
how factors found within the ischemic environment influence release of compounds at 
physiologically relevant doses (Kurtoglu, Navath et al. 2009), the complexity of this environment is 
easily underestimated. Cytokines are released not only in response to the stroke, but potentially 
also in response to the biomaterials themselves. The environment also changes over time from a 
tissue mostly retaining its extracellular matrix and integrity, and possibly limiting the spread of 
nanoparticles (Klose, Laprais et al. 2009) through macrophage infiltration and debris removal to a 
fluid-filled cavity. It is likely that materials will degenerate differently within this evolving 
environment. Time-consuming in vivo studies might therefore be required to establish 
biodegradation profiles and associated factor release, as well as the half life of the released 
product. Degradation characteristics and drug availability could therefore be difficult to estimate. 
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Despite the hopeful preclinical results, more than 49 neuroprotective agents were studied over 
more than 114 clinical trials in the 20th century, and none produced a significant therapeutic effect 
(Kidwell, Liebeskind et al. 2001). This has been attributed to a number of factors causing a 
discrepancy between clinical and preclinical trials, such as the time window and duration of drug 
administration, patient selection criteria, target tissue and outcome measures (Gladstone, Black et 
al. 2002). 
Gene delivery could be an important avenue of treatment for stroke, as it enables steady release 
of protein directly at the site without having to transport large amounts across the BBB. Most gene 
therapy studies for stroke use an intra-cerebral injection (Badin, Modo et al. 2009). These 
injections, however, distribute differentially across the brain parenchyma and are known to result 
in variable expression. Virus-sized particles can improve the biodistribution of therapeutic genes 
in the CNS (Chen, Hoffer et al. 2005). Disulphide bond-based polypeptides are becoming more 
commonly used as vectors, as their cytoplasm-induced reductive response facilitates the release 
of nucleic acids, thereby increasing transfection efficiency (Kim, Jeong et al. 2009, Kim, Lee et al. 
2010). It is important to note that gene therapy can be used not only to target diseased cells with 
survival factors, but also remote regions to support diaschisis, i.e. neuronal plasticity that 
facilitates recovery (Lim, Airavaara et al. 2010). Reducible poly(oligo-d-arginines) (rPOA) can act 
as a carrier of the heme oxygenase-1 (HO-1) gene to decrease apoptosis (Hyun, Won et al. 
2010). Both strategies (i.e. decreasing apoptosis and inducing plasticity) have been demonstrated 
to reduce the impact of stroke. One of the most exciting developments for gene therapy, however, 
would be the conversion of astrocytes in the glial scar into functional neurons (Heinrich, Blum et 
al. 2010).  
Most commonly, a combination of gene- and cell-based therapy is envisaged to improve outcome 
after stroke. As viral vectors will generally indiscriminately transfect host cells where injected, 
transplanted cells can home into areas of damage and provide a flexible gene therapy approach. 
Cells overexpressing various growth factors have been shown to enhance recovery from stroke 
compared to unmodified cells (Kim 2004, Zhu, Zhou et al. 2004, Kurozumi, Nakamura et al. 2005, 
Lee, Lim et al. 2010). 
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1.1.2 Cell Therapy 
Stem cell therapy is proving to be a promising area of research for stroke, with a large number of 
clinical trials now underway. The majority of these trials involve adult stem cells such as 
mesenchymal stem cells, CD34+ hematopoietic progenitors or cord blood stem cells administered 
systemically, and only one targeting intracerebral injection of neural stem cells 
(Clinicaltrials.govKondziolka, Wechsler et al. 2000, Bang, Lee et al. 2005, Kondziolka, Steinberg 
et al. 2005). These trials aim to implement efficacy previously demonstrated in animal studies 
(Borlongan, Tajima et al. 1998, Stroemer, Patel et al. 2009, Wakabayashi, Nagai et al. 2010), but 
so far no robust clinical efficacy has been demonstrated as most trials completed to date are still 
within the safety phase. 
Adult stem cells have gained popularity compared to embryonic and fetal stem cell sources. This 
is due in part to reduced ethical concerns surrounding their use, but also to their safety profile. 
With reduced risk of oncogenesis or aberrant differentiation, and with their survival being mostly 
transient and peripheral, the inherent risk to patients is significantly lower.  
Transplanted stem cells naturally release a cocktail of growth factors (or can be engineered to 
express additional factors), and can thereby provide a localised delivery of factors mentioned 
above and facilitate recovery through the bystander effect. Neural stem cells additionally have the 
potential to directly repair damaged tissue through incorporation into circuitry. At present it is 
unlikely that efficacy of cell transplants is due to a replacement of lost cells or tissues, but instead 
behavioural improvements are generally ascribed to beneficial effects exerted on the host cells 
(Jiang, Zhang et al. 2006). Putative mediators of recovery include regional neuroprotection, 
neuronal plasticity, neurogenesis and angiogenesis (Shen, Li et al. 2010). Transplantation of 
endothelial cells into the stroke-damaged brain reduces the size of infarction and promotes 
behavioural recovery (Fan, Shen et al. 2010, Ishikawa, Tajiri et al. 2013). Not only do these 
endothelial cells improve vascular supply, but they also deliver growth factors that are beneficial 
to the survival of neuronal cells (Moubarik, Guillet et al. 2011). Beneficial effects mediated through 
the vasculature are also thought to underpin improvements associated with intravascular infusion 
or intraparenchymal injection to deliver non-neuronal cells (e.g. bone marrow stem cells, umbilical 
cord cells). These cells typically exhibit low brain penetration and survival. However, even neural 
stem cells (NSCs) vary widely in their survival, with functional recovery being reported even in the 
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absence of significant transplant survival (Saporta, Borlongan et al. 1999). Importantly, NSCs 
implanted into the lesion cavity exhibit poor survival and migrate into existing tissue, rather than 
regenerating the lost tissue (Buhnemann, Scholz et al. 2006). This is significantly different from 
fetal tissue grafts implanted into the lesion cavity. In addition to neural stem cells, fetal tissue 
grafts contain endothelial cells, microglia, extracellular matrix and partially differentiated cells. 
Fetal tissue transplants therefore form a tissue clump within the cavity that poorly integrates with 
the host brain. Still, this “tissue clump” survives with the formation of some axonal connections, as 
well as an integration of blood vessels (Grabowski, Johansson et al. 1995). Survival of fetal grafts, 
in contrast to NSCs, following transplantation may be attributed to the presence of a complex 
microenvironment composed of extracellular matrix, stromal cells, and soluble factors that support 
the fetal progenitors after delivery. This highlights the need for biomaterials or other trophic 
support to deliver, support and improve therapeutic interventions is essential to limit the impact of 
stroke or to replace lost tissue through tissue engineering. 
1.1.3 Tissue engineering 
In situ tissue engineering is a further development of cell therapy (Yu and Morshead 2011). The 
primary aim in the context of stroke is to generate de novo tissue that could integrate into neural 
networks and contribute to recovery of function. Additionally, however, the lesion cavity provides 
an opportunity for delivery of a much higher dose of therapeutics directly to the site of injury 
without increasing damage to healthy tissue. In order to generate new tissue, not only will 
implanted cells need to remain and survive within the lesion cavity, but there is also a requirement 
for a vascular network and site-appropriate differentiation, as well as integration with the host 
brain tissue. Growth factors can be secreted from biomaterials to guide these processes (Lam, 
Patel et al. 2010). However, the number of processes involved is staggering and dynamic. Similar 
processes are well described in both mammalian development and invertebrate regeneration 
(Tanaka and Ferretti 2009). However the unique situation of mammalian brain regeneration will 
require an equally unique set of processes to ensure that an appropriate tissue forms. Although 
some processes will be similar to those seen in development (Cramer and Chopp 2000), it is 
likely that they will be orchestrated in a different way, with sequence alteration and some entirely 
different processes.  
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The simplest approach to enhance the survival of transplanted cells within the lesion cavity is to 
provide some structural support. A wide variety of biomaterials appear to be compatible with 
neural stem cells (i.e. allow survival and differentiation) (Thonhoff, Lou et al. 2008), but long-term 
testing under biodegradable conditions are required to establish the influence degraded scaffold 
components exert on cellular fate. Intra-lesion transplantation of neural stem cells with 
biomaterials can lead to the formation of a primitive neural tissue in the cavity as support 
materials degrade (Park, Teng et al. 2002, Bible, Chau et al. 2009). Hydrogel support significantly 
increases survival of neural progenitors within the lesion cavity (Zhong, Chan et al. 2010). It 
remains unclear if these approaches will translate into improved efficacy, however transplantation 
of neural stem cells on polymer scaffolds has been shown to improve recovery after traumatic 
injury of the spinal cord (Teng, Lavik et al. 2002, Olson, Rooney et al. 2009, Chen, Hu et al. 
2010). 
Although structural support appears essential to retain NSCs within a lesion cavity, it is unlikely 
that this will be sufficient to produce behavioural recovery or tissue regeneration. A demonstration 
of functional de novo tissue is a much more challenging aim. For instance, even if NSCs establish 
connections between themselves, they require the supply of nutrients through blood vessels. 
Unless an efficient and sufficient vascular supply can be established, it is unlikely that NSCs will 
prosper. Co-transplantation of endothelial and neural stem cells, as well as in vitro pre-formed 
neurovascular units, could overcome this issue. A controlled factor release from biomaterials is 
likely to be required though to ensure a concerted response and integration with the host brain. 
For example, Saif et al. (2010) have shown that a scaffold producing VEGF, Hepatocyte Growth 
Factor and angiopoietin-1 enhanced neovascularization in hind limb ischemia compared to cell 
therapy alone. Bible, Qutachi et al. (2012) showed recruitment of endothelial cells to the stroke 
lesion after co-transplantation of NSCs with VEGF-releasing microparticles. A further factor to 
consider is the site-appropriate differentiation of transplanted cells. This would be particularly 
important when transplanting directly into the lesion. Although relevant differentiation cues may be 
present at the periphery of the lesion, they are unlikely to be present in the core of the neuro-
scaffolding. Small synthetic molecules can, however, be used to promote the striatal 
differentiation of human neural stem cells (El Akabawy, Martinez-Medina et al. 2011). An in vivo 
directed differentiation is therefore conceivable. Nevertheless, the logistics in combining neural 
stem cells with biomaterials is considerable and requires detailed protocols that can be easily 
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transferred between different sites. Success will also heavily depend on novel non-invasive 
imaging approaches that allow transplantation at an appropriate time point into a suitable site 
(Bible, Chau et al. 2009). Where the aim is to fill the lesion cavity with material and/or cells, the 
ECF currently occupying the lesion must also be taken into account, and potentially drained to 




1.2 Identifying grafted cells 
As cell therapy moves forward, elucidation of the therapeutic mechanisms relies on the reliable 
identification of transplanted cells within host tissue. Not only is the location of the cells indicative 
of their function, but also allows co-localisation with phenotypic markers to ascertain functional 
processes. Identification techniques must avoid false positives, false negatives and observer 
effects, all of which can lead to misguided conclusions regarding cell fate and effects.  
False positive refers to the errant identification of a host cell as a transplanted cell, and can occur 
due to leakage of labels, or background signal (Figure 1.2B). In the context of intracerebral 
transplantation, false positive identification can result in an overestimation of surviving cells, and 
erroneous conclusions regarding their fate. The identified cell may be a neuron that is clearly 
integrated into host tissue, leading the investigator to conclude that the therapeutic mechanism of 
the transplanted cells is via cell replacement. However, this result could also be explained by 
label leakage into host cells, and transplanted cells may not have integrated, or indeed not 
survived. 
False negative refers to errant identification of transplanted cells as host cells (Figure 1.2C). This 
can be due to a <100% presence of the marker in the transplanted cell population, or to later loss 
through label breakdown or dilution or changes in cell phenotype, and results in underestimation 
of transplant survival. Depending on the type of marker used, an identification bias may also be 
introduced, skewing the sample of cells from which the therapeutic mechanism is deduced. For 
example, using species specific nestin expression to identify xenotransplanted neural stem cells 
may later exclude cells that have differentiated into neurons and downregulated nestin 
expression. This could lead to conclusions that transplanted cells did not differentiate when this 
may not be the case. 
The observer effect refers to the term coined in physics where the act of observing a system 
influences its behaviour. By applying labels to transplanted cells for identification purposes, the 
biology of the cells and therefore their therapeutic effect, may be significantly altered (Figure 
1.2D). Labels have been shown to affect cell biology in vitro (Lehner, Sandner et al. 2011), and 




Figure 1.2 Considerations in marker selection for reliable cell identification. Accurate identification identifies 
only transplanted cells, and does not affect their biology (A). Presence of the identification marker in host 
cells generates false positives (B), whereas absence of the marker from transplanted cells generates false 
negatives (C). The observer effect refers to an effect of the identification marker on the biology of 
transplanted cells (D). 
 
1.2.1 Histological visualisation of transplanted cells 
Histological techniques offer unparalleled resolution, and the opportunity to combine cell 
identification with antibody labeling of relevant biological molecules. This is therefore the 
technique of choice to look at cell differentiation, receptor expression, immune response and a 
host of other processes. It has been widely used over a number of decades and is therefore well 
trusted, although this can at times leave the door open for insufficient rigour and cross validation.  
There are many types of optical label, but all can be broadly categorized by their intracellular 
localisation. This gives three main categories – nuclear, cytoplasmic and membrane bound. The 
localisation of the dye affects not only the cell’s appearance and ease of identification, but also 
any potential cellular effects. 
1.2.1.1 Immunohistochemical techniques 
Using endogenous characteristics of the transplanted cells is a very attractive option as it requires 
no interference with the cells prior to transplantation, thereby eliminating observer effects, and is 
often highly accurate and reliable. A common example is the use of species specific antibodies. 
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Human cells are often transplanted into rodent models in pre-clinical studies, and can be 
identified by human-specific antibodies such as human nuclear antigen (HNA) and Ku80 
(STEM101) (Smith, Stroemer et al. 2011, El-Akabawy, Rattray et al. 2012). This of course only 
works in a xenograft situation. Additionally, techniques such as in situ hybridization (ISH) allow 
separation on the basis of genomic DNA, such as an immortalisation construct in the context of 
cell line transplants, or the presence of a Y chromosome to allow gender distinction. This can 
potentially be used even in an allograft scenario, but does of course exclude autograft.  
BrdU (5-bromo-2'-deoxyuridine) is a thymidine analogue, which is incorporated into DNA in place 
of thymidine during DNA synthesis and can later be detected using immunohistochemistry. It has 
been used for identification of grafted cells since the ‘80s (Brown and Stanfield 1989). There are 
other thymidine analogues using alternate halogens such as Chlorine (CldU) or Iodine (IdU), but 
BrdU remains the most widely used, and has been shown to be more sensitive (Leuner, Glasper 
et al. 2009).  Although the tight incorporation of BrdU into DNA results in a lower propensity for 
leakage per se, cell death results in the release of BrdU into surrounding tissue, and it has been 
shown to be transferred to host cells (Burns, Ortiz-Gonzalez et al. 2006). The addition of BrdU to 
cells prior to transplantation additionally re-introduces the potential for observer effects since it 
has been shown to affect cell biology (Caldwell, He et al. 2005, Lehner, Sandner et al. 2011). 
1.2.1.2 Nuclear markers 
Nuclear labels include those that bind to DNA such as DAPI (4',6-diamidino-2-phenylindole) and 
Hoechst, and reporter genes such as GFP and mCherry.  
DAPI and Hoechst are most commonly used as nuclear counterstains for fluorescence histology 
due to their bright fluorescence, high efficiency and ease of labeling. Both are also used to label 
live cells for identification post-transplant (Elmadbouh, Chen et al. 2005, Rossignol, Boyer et al. 
2011) but have been criticised by some for their propensity to leak into host cells (Iwashita, Crang 
et al. 2000, Castanheira, Torquetti et al. 2009). Additionally, Hoechst has been shown to be both 
toxic (Durand and Olive 1982, Singh, Dwarakanath et al. 2005) and non-toxic to cells (Hubbard, 
Gut et al. 2012), showing that its cytotoxicity is highly dependent on conditions and assays used. 
Both DAPI and Hoechst bind to AT rich regions of DNA (Vega, Garcia Saez et al. 1994), which is 
where many transcription factors bind (Privalov, Dragan et al. 2007). Hoechst has been shown to 
upregulate the pro-survival factor Survivin, and in doing so attenuate the effects of its own 
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cytotoxicity (Wu, Apontes et al. 2007). Transcription factors such as Mash1, which plays a role in 
neural commitment, also bind to AT rich regions (Ghysen, Dambly-Chaudiere et al. 1993), but 
population level effects on cell differentiation have not been shown. 
Reporter genes refers to the insertion of a gene into the cells such that when it is transcribed, the 
product will be visible to the selected imaging modality. The most well-known example is probably 
Green Fluorescence Protein (GFP) which, as the name suggests, is fluorescent and therefore 
visible using fluorescence microscopy. This mechanism means that  cells are only detected when 
viable and producing protein, and that the product cannot leak into host cells. This reduces the 
likelihood of false positives, but the similarity of the fluorescence to autofluorescence can still 
cause cases of mistaken identity (Spitzer, Sammons et al. 2011, Molcanyi, Bosche et al. 2013). 
Protein expression is often highly variable across the cell population, and gene silencing can 
occur after transplantation, depending on the promoter used, leading to a loss of fluorescence 
over time. Expression of a reporter gene can also induce marked changes in cell biology (Huang, 
Aramburu et al. 2000, Martinez-Serrano, Villa et al. 2000), and some concern has been raised 
over potential immunogenicity of the proteins themselves (Bubnic, Nagy et al. 2005). However, 
reporter genes have great potential, and improvements in the design of promoters as well as cell 
lines with safe insertion sites mean that many of these problems may be overcome in the future. 
1.2.1.3 Cytoplasmic labels 
The most well known cytoplasmic label is probably carboxyfluorescein succinimidyl ester (CFSE). 
It is applied to cells as the highly membrane permeant compound carboxyfluorescein diacetate 
succinimidyl ester (CFDASE), which is then cleaved within the cell to give CFSE, a much less 
permeant molecule which is fluorescent and can be coupled to intracellular molecules to achieve 
stable labeling (Parish 1999). It is particularly well suited to labeling lymphocytes, and quantifying 
their proliferation, although reports of its cytotoxicity vary (Last'ovicka, Budinsky et al. 2009, Quah 
and Parish 2010). Labeling of preadipocytes showed low labeling efficiency and high cell toxicity 
(Hemmrich, Meersch et al. 2006). CFSE is not widely used for intracerebral transplantation. Only 
two incidences of labeling neural cells is available in the literature, and little analysis of label 
effects or leakage were performed (Li, Dancausse et al. 2003, Wang, Schwindt et al. 2009). 
Quantum dots are a newer technology, and represent a very broad category of particles. The 
defining characteristic is that they are semiconductor nanoparticles whose absorption/emission 
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wavelengths can be tuned via alteration of the size of the particle, with larger particles having 
longer wavelength spectra (Dabbousi, Rodriguez-Viejo et al. 1997). Their advantages include 
photostability, narrow emission spectra, capacity for addition of targeting moieties, and the 
potential to be used for in vivo tracking (Walling, Novak et al. 2009). However, their size 
differences can affect label uptake and retention (Seleverstov, Zabirnyk et al. 2006), and the 
particles can be made of and coated with a large variety of different materials (Anilkumar, Wang 
et al. 2011, Kuo, Chueh et al. 2011, Ryvolova, Chomoucka et al. 2011, Wang, Mo et al. 2011), 
each of which may alter particle effects on labeled cells (Hoshino, Hanada et al. 2011). The cell 
type and even differentiation state could also be important. For example, in a neuronally 
differentiating, raphe-derived cell line, fluorescent microspheres were shown to be toxic to 
differentiated cells, but not to the proliferating progenitors (Onifer, White et al. 1993). 
1.2.1.4 Membrane dyes 
Lipophilic dyes, such as PKH26 and DiR (3,3,3’,3’ tetramethylindotricarbocyanine iodide), 
incorporate into lipid regions of the cell membrane. They give a very bright fluorescence, although 
it is somewhat susceptible to bleaching, and are very simple to use. However, the membrane is 
constantly turned over as sections are used to form endosomes and exosomes, with some 
phagocytes turning over their whole membrane in 30min (Gheber and Edidin 1999). This 
inevitably leads to some leakage of the dye, and in one transplantation experiment, 88% of DiR 
labeling was shown to be due to host microglia rather than transplanted cells (Lassailly, 
Griessinger et al. 2010). However, this was after intravenous injection of cells, and little has been 
reported on the label’s behaviour in the context of transplantation into brain tissue. However, its 
use as a retrograde and anterograde neuronal tracer has been investigated (Kawaguchi, 
Katsuyama et al. 2010) 
1.2.2 Non-invasive imaging 
Histology offers many advantages in terms of its resolution and ability to assess the presence of 
proteins in host tissue and transplanted cells. For example, caspase 3 can be used to assess 
apoptosis (Chen, Ma et al. 2015), and phenotype markers can assess cell differentiation and 
endothelial cell infiltration. However, its very significant drawback is the need to harvest and 
process tissue, meaning that looking at transplanted cells over time requires numerous cohorts of 
animals. This of course introduces ethical considerations, as well as monetary and logistical 
28 
 
concerns, but importantly means that one is not in fact observing the cells “over time”. This is 
particularly important in highly variable models, such as MCAO (Smith, Stroemer et al. 2011) 
where there are several “layers” of variability, beginning with lesion size and topology and 
extending through cell delivery and survival, and immune response. Therefore, in order to obtain 
a true picture of the overall process and the factors affecting it, better ways of monitoring cells in 
vivo are required. There are now a wide variety of imaging techniques available, the advantages 
and disadvantages of which (for cell tracking) are summarised in Table 1.1. 
The ideal in vivo imaging technique would allow reliable identification of transplanted cells, as 
described above, and also provide anatomical information, so that the cells’ location, survival and 
movement relative to the lesion can be accurately determined, and also so that changes in the 
lesion itself can be analysed, such as lesion volume. Although lesion volume alone is not 
necessarily a reliable measure of therapeutic outcome, it remains a useful measure when 
elucidating the therapeutic mechanism of transplanted cells. In order to measure the therapeutic 
effect in a way that is meaningful in terms of predicting its clinical efficacy, behavioural measures 
are essential, since regaining motor and cognitive functions is the primary clinical goal.  
1.2.2.1 Optical Imaging 
Light is commonly used in histological techniques, but in vivo it suffers from a high level of scatter. 
The use of longer wavelengths of light, such as red and near infra red (NIR) reduce this problem, 
but the main limitation of light based imaging remains tissue penetration. This is a particular 
problem in the brain, where tissue is fixed within the skull, so penetration of two very different 
tissue types would be required for truly non-invasive imaging. The main light-based techniques 
used in rodent stroke models are Bioluminescence and two-photon microscopy. 
Two photon microscopy (TPM) is most commonly used following a craniotomy, where a portion of 
the skull is removed to allow direct access to brain tissue. This enables imaging up to 300-500µm 
below dura using GFP (Kozai, Vazquez et al. 2012). TPM is useful for imaging immediate 
inflammatory processes (Hasenberg, Hasenberg et al. 2015), as well as angiogenesis and BBB 
integrity (Masamoto, Takuwa et al. 2013) but due to the required craniotomy or skull thinning, long 
term repeated imaging is not usually performed using this technique. In MCAO, the location of the 
lesion is normally at least 4-5mm below dura, which is out of range for this method (Kerr and 








Bioluminescence (BLI) refers to the use of luciferase enzymes that catalyse light-emitting 
reactions as reporter genes in transplanted cells. There are a number of luciferases available 
from different species, which have different emission spectra affecting their in vivo utility (Zhao, 
Doyle et al. 2005). Firefly luciferase (fluc) is the most commonly used, due to its longer 
wavelength and consequent reduced scatter in vivo. In order to detect transplanted cells 
expressing luciferase, luciferin is then administered to the animal, and luciferase catalyses the 
reaction between luciferin, adenosine triphosphate (ATP) and oxygen, during which light is 
released and detected (Figure 1.3). For a given fluc+ cell line, a standard curve can be set up to 
give a quantitative readout of cell number from a given readout of light emission (Bernau, Lewis et 
al. 2014). 
 
Figure 1.3 Mechanism of BLI. Luciferase expressed by modified cells catalyses the conversion of luciferin to 
oxyluciferin in the presence of ATP, oxygen and magnesium. 
 
BLI is a very attractive option for cell tracking due to the relatively low cost of equipment (Inoue, 
Kiryu et al. 2009) and ability to report on cell viability due to the requirement for ATP and oxygen. 
In vivo detection in the rat striatum has been demonstrated at 9 x 105 transplanted cells over 12 
weeks, with a detection threshold between 9 x 103 and 9 x 104 cells (Bernau, Lewis et al. 2014). 
Imaging endogenous NSCs, where luciferase expression is under the control of the nestin 
promoter in a transgenic mouse has been demonstrated at 2,000 NSCs (Vandeputte, Reumers et 
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al. 2014). The differences here may be due to a number of factors such as relative tissue depth in 
the two species, the level of luciferase expression, and availability of luciferin and oxygen from the 
blood, which may be higher for the well-vascularised SVZ compared to newly grafted cells. This 
may be an additional consideration for transplantation into a hypoxic environment. Assessing the 
relationship between oxygen/luciferin availability and light emission in vitro way well be an 
essential first step before utilising this method in an environment such as the lesion cavity. 
However, BLI has been successfully used to assess the temporal expression profile of VEGF2 
after stroke in a transgenic mouse model (Adamczak, Schneider et al. 2014), and therefore may 
be useful in assessing the peri infarct environment and informing the design of factor releasing 
scaffolds. 
A third optical method with potential applications here is optogenetics, where neuronal activity is 
linked to light. This can either be the application of light to provoke neuronal activation through 
e.g. channelrhodopsin, or the activation of fluorescence in the presence of intracellular calcium 
through genetically encoded calcium indicators (GECIs, such as GCaMP). These techniques 
allow assessment of the connectivity of grafted cells to host tissue, (Byers, Lee et al. 2015, 
Steinbeck, Choi et al. 2015) and the use of GECIs would also allow assessment of spontaneous 
graft activity. 
However, the need to incorporate a reporter gene has its own disadvantages for cell tracking (see 
section 1.2.1.2 above), and the lack of anatomical information is problematic, particularly in the 
context of tissue engineering. Combining bioluminescence with MRI, however, shows promise in 
overcoming this issue (Tennstaedt, Aswendt et al. 2013). 
1.2.2.2 Nuclear Imaging 
Nuclear imaging methods are based on the use of gamma or x rays, which have a very high 
frequency (3 x 1016 – 3 x 1019 Hz), and as such, they carry inherent safety concerns (Zanzonico, 
Dauer et al. 2008). The dose received by patients in medical imaging is a very small proportion of 
what they are exposed to annually from background radiation, but radiographers working regularly 
with these modalities require protective equipment. 
Nuclear imaging modalities include positron emission tomography (PET), single photon emission 
computed tomography (SPECT) and x-ray computed tomography (CT). PET and SPECT both 
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have extremely high sensitivity, but the short half life of most radioligands and the lack of 
anatomical information means that these have not been modalities of choice for cell tracking. 
However, these can be combined with MRI or CT to provide anatomical context (Gildehaus, 
Haasters et al. 2011), and genetically modified cells can be used to over come the short half life. 
Herpes Simplex Virus type 1 thymidine kinase (HSV1-tk) can be used to entrap systemically 
administered probes such as 18F-fluoropenciclovir (18F-FPCV) within genetically modified cells 
(Iyer, Barrio et al. 2001). However, like BLI this relies on delivery of the probe through the blood, 
and visualisation may therefore be hampered by cell localisation within the poorly vascularised 
lesion environment. [(18)F]fluorodeoxyglucose (18FDG) is a radioactive glucose analogue, which 
can be used to measure glucose uptake to report on tissue metabolism during a stroke (Balsara, 
Chapman et al. 2014) or over time through recovery (Martin, Gomez-Vallejo et al. 2013). It can 
also be used to report on changes in dopamine binding activity using [(11)C]raclopide (Martin, 
Gomez-Vallejo et al. 2013). These two techniques, when combined with CT, provide insight into 
stroke pathology and recovery. When combined with the HSV1-tk system to identify transplanted 
cells, it would be possible to asses the metabolic activity and dopamine binding of transplanted 
tissue, providing a wealth and specificity of information not available using other imaging 
techniques. 
1.2.2.3 Magnetic Resonance Imaging (MRI) 
MRI is a tomographic imaging technique with good spatial and temporal resolution, no tissue 
depth limitations and no need for ionizing radiation. It is most often tuned to 1H nuclei, 
predominantly measuring the water protons present in all tissue. These nuclei have a property 
known as spin, and their movement within an electromagnetic coil creates small voltages that can 
be detected. Their equilibrium is disturbed by the application of a radiofrequency (RF) pulse, and 
the time take to return to equilibrium (relaxation) is measured. Tissue contrast is generated due to 
the effects of the environment on different aspects of relaxation, namely T1 and T2. In order to 
track transplanted cells, contrast agents are added, which affect the T1 and T2 relaxation 
properties of protons within the cells. Contrast agents are normally grouped as T1 or T2 agents 
based on which property they have the most significant effect on. However, it should be noted 
that these two properties are closely related, so agents will always affect both to some extent. 
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The most commonly used contrast agent for cell tracking is iron, either in the form of 
nanoparticles (super paramagnetic iron oxides, SPIOs) (Guzman, Bliss et al. 2008), or with the 
use of the ferritin reporter gene, which increases uptake of iron from the blood and surrounding 
tissue (Iordanova and Ahrens 2012). Their predominant effect is on T2 contrast, and excellent 
sensitivity has been achieved. They have been widely used to track migration of transplanted 
cells in the brain (Hoehn, Kustermann et al. 2002, Jendelova, Herynek et al. 2003, Guzman, Bliss 
et al. 2008, Kallur, Farr et al. 2011). However, iron is an abundant element in the body and as 
such a T2 hypointensity can be produced by naturally occurring phenomena such as dilated blood 
vessels, intracerebral bleeds, or tissue damage such as an injection tract, and these can be 
difficult to distinguish from transplanted cells. Infiltrating immune cells also incorporate iron from 
their environment and produce T2 hypointensity border regions of a stroke lesion (Vandeputte, 
Thomas et al. 2010). Additionally, T2 weighted images are the method of choice for assessing 
changes in lesion volume over time, for example using deformation based morphometry (Smith, 
Stroemer et al. 2011) so being able to image cells without interfering with this would be an 
advantage.  
A second class of MRI contrast agents are dubbed T1 agents, as they produce a hyperintensity 
on T1-weighted MR images. The most commonly used T1 contrast agent for cell tracking is 
Gadolinium (Gd). It is less sensitive than iron-based contrast agents (Helm 2010), but the ability 
to unambiguously identify cells on T1-weighted images is a significant advantage. Gd-labeled 
cells show the same migratory patterns as iron labeled cells (Modo, Mellodew et al. 2004). 
However, despite not showing significant effects on cell biology in vitro (Brekke, Morgan et al. 
2007), labeled cells had reduced therapeutic efficacy compared to those labeled with the 
histological label PKH26 (Modo, Beech et al. 2009). 
Although MRI is most often tuned to 1H nuclei, it is also possible to tune to alternate nuclei such 
as  Fluorine-19 (19F). This has the advantage that there is no background signal in the body, 
allowing unambiguous detection, but the sensitivity is lower still than Gd, requiring large cell 
numbers for detectable signal (Boehm-Sturm, Mengler et al. 2011, Bible, Dell'acqua et al. 2012). 
Further applications of MRI in stroke include Blood Oxygen Level Dependent (BOLD) fMRI to 
observe tissue oxygenation levels (An, Liu et al. 2012), and neuronal tracing techniques such as 
Manganese Enhanced MRI (MEMRI) to observe changes in connectivity (van der Zijden, Wu et 
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al. 2007). MEMRI also offers the potential for combination with PET through the use of radioactive 
(52)Mn (Lewis, Graves et al. 2015, Weissler, Gebhardt et al. 2015), but care must be taken as it 
has been shown to be cytotoxic, and long term exposure can induce symptoms similar to 
Parkinson’s Disease (Olanow 2004). 
The main drawback of MRI is its low sensitivity. Differences between tissue must be very 
significant before noticeable MR contrast is observed. However, the anatomical information is 
highly valuable. In particular, the ability to distinguish between a fluid-filled cavity and organized 









1.3 Image Guided Injection 
Imaging can guide cell injection in a number of ways; to select subjects, to position injections to 
minimise damage, and to optimise placement of injected materials on an individual basis. Subject 
selection for inclusion in an efficacy study is routine in clinical trials (Yoo, Pulli et al. 2011), but is 
not yet common practice in preclinical studies. For instance, inclusion and exclusion criteria for an 
efficacy study could define a minimum hyperintense area on T2-weighted MR images. Very small 
lesions (e.g. <10 mm3 in the rat) revert to isointense contrast over 14 days and should therefore 
be excluded if lesion volume is one of the main outcome measures. Therefore it is important to 
have a robust imaging paradigm to detect the evolution of the lesion (Helpern, Dereski et al. 1993, 
Knight, Dereski et al. 1994). A very large lesion also affects efficacy, with lesions confined to the 
striatum showing improved behavioural outcome after NSC transplant compared to lesions 
spanning striatum and cortex (Smith, Stroemer et al. 2011). 
Placement of injected materials is also an important consideration. Cell injection into parenchymal 
tissue has been shown to produce improved behavioural outcome compared to transplantation 
into the ventricles (Smith, Stroemer et al. 2011). Since the lesion varies in size and location 
between individuals, treatment efficacy may be improved by individualising dosage and 
placement of cells. Accidental placement into the lesion cavity rather than parenchymal tissue is 
likely to reduce cell survival and efficacy. Conversely, when targeting the lesion for tissue 
engineering, the large volume of cells and biomaterials required to fill the lesion could cause 
extensive damage if injected into healthy tissue (Bible, Chau et al. 2009, Massensini, Medberry et 
al. 2014).  
The use of image guidance for transplantation requires anatomical imaging with good contrast 
between soft tissue types. CT and MRI are both able to provide sufficient information, but MRI 
provides improved soft tissue detail, and techniques such as fluid-attenuated inversion recovery 
(FLAIR) and diffusion weighted imaging (DWI) allow more precise delineation of lesion cavity 
compared to parenchymal tissue (Bible, Dell'acqua et al. 2012). 
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1.4 Imaging in tissue engineering 
1.4.1 Imaging Biomaterials 
Some biomaterials will have relaxivity properties and can therefore be easily detected using MRI, 
but this inherent contrast will make it difficult to interrogate what changes occur within the lesion 
territory (Bible, Chau et al. 2009). Therefore a tuneable or induced contrast in biomaterials might 
be desirable. Incorporating contrast agents into biomaterials, such as hydrogel, can make these 
visible on MRI without interfering with structural T2-weighted images (Karfeld-Sulzer, Waters et al. 
2011, Kim, Chun et al. 2012). The release of contrast agents from biomaterials in conjunction with 
the release of growth factors also potentially provides a means to monitor their distribution and 
release kinetics in vivo (Onuki, Jacobs et al. 2010). This provides an opportunity to understand 
how factors released from biomaterials interact with the host brain. Multifunctional and multi-
modal materials (Yim, Seo et al. 2011) might therefore be needed to allow the simultaneous 
monitoring of various processes. Detection of biomaterials used to engineer tissue, however, 
should not interfere with the visualization of tissue formation. 
1.4.2 Multiple Transplant Components 
The increasing complexity of transplants for tissue engineering introduces the problem of multiple 
transplant components. Although one option would be to simply track “the transplant” with a single 
contrast mechanism, it is important to elucidate the mechanisms of each component’s 
contribution to the therapeutic effect. Being able to independently track one or more cell 
populations as well as the degradation of a biomaterial would enable much swifter and more 
accurate evolution of tissue engineering therapies.  
1.4.3 Monitoring Tissue Formation 
Only T2-weighted MR images will be insufficient to demonstrate tissue formation (Bible, 
Dell'acqua et al. 2012). Conventional MR contrast agents affect 1H and therefore are likely to 
affect T2-weighted images, whereas novel classes of contrast agents, such as 19F or chemical 
exchange saturation transfer (CEST), are likely to be better candidates to report on the presence 
of biomaterials. However, for regenerative imaging, it is even more important to be able to 
visualize biological processes rather than the biomaterials. 
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In the absence of existing tissue, there are no cues to instruct site-appropriate differentiation of 
implanted cells. These cues need to be delivered through biomaterials or pre-differentiation of 
cells (El Akabawy, Martinez-Medina et al. 2011). The molecular signature of the tissue can 
potentially be monitored non-invasively using magnetic resonance spectroscopy (MRS) 
(Manganas, Zhang et al. 2007, Loewenbruck, Fuchs et al. 2011). MRS can establish a particular 
metabolite profile for a given tissue, such as striatum or cortex, as these metabolites are 
dependent on the variety of elements contained within the tissue (Brownell, Chen et al. 2004), 
and they thereby provide a very general means to establish what aspects of the appropriate 
tissue have been regenerated (Ross, Hoang et al. 1999). For instance, MRS of the rat striatum 
clearly indicates the presence of GABA and glutamate (Roffman, Lipska et al. 2000), two key 
neurotransmitters in this neuroanatomical structure. Therefore any replacement tissue needs to 
demonstrate that similar levels of neurotransmitters can be generated. Additionally, MRS can 
report on the health of the tissue with lactate being upregulated in dying cells (Woo, Lee et al. 
2010) and phosphocholine being upregulated in proliferating cells (Gillies, Barry et al. 1994). 
Future studies have to nevertheless demonstrate that MRS can indeed provide a reliable 





Aims and Objectives 
This project has 3 specific aims: 
• To compare currently used histological labels to assess their reliability for identifying cells 
transplanted into the brain and determine which, if any, are suitable for use in further 
studies 
• To assess the suitability of a novel gadolinium-gold nanoparticle for visualising 
transplanted cells in vivo using MRI 
• To assess the potential of two paraCEST agents for independent visualisation of two cell 
populations in vivo   
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Chapter 2: Histological labels for identification 
of transplanted cells   . 
2.1 Introduction 
Due to its excellent resolution, suitability for probing cell phenotype and function, and relatively 
low cost, histology remains the most widely used method of tissue analysis. In particular, 
fluorescence immunohistochemistry is extremely versatile, as a number of different channels can 
be used to assess different cell characteristics. Being able to reliably identify transplanted cells is 
vital in order to establish their fate after transplantation, and thereby elucidate their therapeutic 
mechanisms. In xenograft studies, species-specific antibodies can be used for this purpose. 
However, in the context of allo- or auto-graft, or where more than one population is transplanted, 
it becomes necessary to add an exogenous label to grafted cells in order to identify them. 
Histological labels have been used since the early 90s (Sprick 1991, Trumble and Parvin 1994), 
and concerns about their effects on labeled cells were raised almost immediately (Samlowski, 
Robertson et al. 1991). However, the majority of early studies were focused on labeling of 
lymphocytes, either in situ or on intravenous injection of labeled cells. Studies on intracerebral 
transplantation of labeled cells primarily used toxicity tests, such as Trypan Blue exclusion, to 
assess the effects of labels on transplanted cells, and it has only been more recently that 
concerns have been raised regarding their more subtle cellular effects (Lehner, Sandner et al. 
2011) and leakage in vivo (Iwashita, Crang et al. 2000, Burns, Ortiz-Gonzalez et al. 2006). 
However, there are a wide variety of labels available, with different methods of incorporation, 
which may have different effects on labeled cells, and on the label’s propensity for leakage. These 
have not been directly compared in the same context, so it is currently difficult for investigators to 
make an informed choice regarding selection of a reliable label. In order to be described as 
reliable, a label should 1) Efficiently label all required cells, 2) Have minimal effects on the cell’s 
biology and 3) Not be lost or diluted from transplanted cells, or transferred to host cells.  
In this study, we aim to test four labels using these criteria in order to draw a direct comparison of 
their suitability for identifying transplanted neural stem cells. Transplantation of human neural 
stem cells into healthy rat brain tissue allows the use of a species-specific antibody to reliably 
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distinguish transplanted from host cells, allowing the comparison of its localisation with that of the 
labels tested in order to deduce the comparative accuracy and reliability of each label. 
2.2 Methods 
2.2.1 Experimental Design 
Experiments were designed to investigate four major questions: 
1. Are all cells labeled, or would there be false negatives? 
2. Are there cellular effects of the label? 
3. Is there leakage and re-uptake of the labels that would lead to false positives? 
4. How reliable are labels to identify implanted cells in vivo? 
Based on these questions, a flow diagram (Figure 2.1) can be drawn that determines the 
suitability of a given label to progress to the next step of testing. Multiple potentially suitable labels 
can therefore be compared using these steps to determine which are reliable for in vivo 
identification of cells. To this end, six histological labels were investigated: Fast Blue, Hoechst, 




Figure 2.1. Experimental Design. Labels will undergo a battery of tests with the STROC05 neural stem cell 
line to determine their reliability. 
The cell line selected for use is the STROC05 fetal neural stem cell line. This line is a promising 
candidate for tissue replacement after stroke, and has shown the capacity to form primitive neural 
tissue in the stroke cavity (Bible, Qutachi et al. 2012). The properties of these cells have been 
well characterised (El Akabawy, Martinez-Medina et al. 2011), enabling reliable detection of 
deviations caused by the presence of a label. Their characteristic expression of phenotypic 
markers before and after differentiation is shown in Figure 2.2A. An increased expression of 
GFAP, Tuj and Galc at day 7 and decreased expression of Ki67 is evident compared to day 1. 
The use of a human line here allows the use of species-specific (human) antibodies (Figure 2.2B) 
to identify these cells against a rat tissue background, since rat tissue does not react with these 
(Figure 2.2C). A positive control to show that these antibodies detect human cells was performed 




Figure 2.2. STROC05 Neural Stem Cells stained with a proliferation marker, Ki67 and markers of different 
cell lineages (GFAP for astrocytes, Tuj for neurons and Galc for oligodendrocytes) at day 1 and day 7 (A). 
STROC05 cells are positive for human specific markers HNA and SC101, and HSP27 (B). Rat tissue is 
negative for HNA (C) and human tissue is positive (D). 
 
To address the questions in the flow chart above, the in vitro experiments were set up as shown 
in Figure 2.3. Specifically, after labeling, cells were tested immediately for viability. 24 hours later, 
extent of cell labeling and label transfer were assessed, in addition to viability (%), number of 
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surviving and proliferating cells, and expression of phenotypic markers. After 7 days, retention of 
label, survival, proliferation and phenotypic markers were measured again to establish potential 
delayed effects of the labeling procedure. 
 
Figure 2.3. In vitro methods, showing parameters assessed at day 1 and 7. 
 
2.2.2 Cell culture 
2.2.2.1 STROC05 Cell line 
The cMyc-ERTAM striatal neural stem cell line STROC05 (ReNeuron) was previously described by 
Johansson et al. (2008). Briefly, cells isolated from the whole ganglionic eminence of a 12 week 
old human fetal brain were transfected with the cMyc-ERTAM gene, encoded by the retroviral 
vector pLNCX-2 (Clontech) and transfected colonies were selected using neomycin resistance 
and expanded into a clonal cell line (Pollock, Stroemer et al. 2006). 
STROC05 cells were grown in vitro as monolayers in T-flasks (Falcon) coated with mouse laminin 
(10µg/ml, Sigma L2020) for 1.5 hours at 37°C. The proliferation medium used was DMEM:F12 
(Sigma D6421) supplemented as shown in Table 2.1, with the addition of 4-hydroxy-tamoxifen 
ensuring proliferation through the conditional immortalization gene. Cells were kept in a 
humidified-atmosphere incubator at 37°C, with 5% (v/v) CO2, and medium was changed every 2 
days. Cells were tested for mycoplasma infection regularly using the Invivogen PlasmoTest kit 





Table 2.1. Components added to DMEM-F12 basal medium for STROC05 proliferation medium. For 
differentiation medium, bFGF, EGF and 4-hydroxy-tamoxifen were omitted. 
Component Source Final Concentration 
Human Albumin Solution GemBio 800-121 0.03 % 
Transferrin, human Sigma T1147 100 µg/ml 
Putrescine DiHCl Sigma P5780 16.2 µg/ml 
Insulin, human recomb. Sigma I9278 5 µg/ml 
L-Thyroxine (T4) Sigma T0397 400 ng/ml 
Tri-iodo-thyronine (T3) Sigma T6397 337 ng/ml 
Progesterone Sigma P8783 60 ng/ml 
L-glutamine Sigma G7513 2 mM 
Sodium Selenite Sigma S9133 40 ng/ml 
Heparin Sodium Sigma H3149 10 units/ml 
Corticosterone Sigma C2505 40 ng/ml 
bFGF PeproTech 100-18B 10 ng/ml 
EGF PeproTech AF-100-15 20 ng/ml 
4-hydroxy-tamoxifen (4-OHT) Sigma H7904 100nM 
 
Cells were passaged at 70-80% confluence using a standard protocol. Briefly, media was 
removed, cells washed once with HBSS (LifeTech) and Accutase (Sigma) was added to the 
monolayer, and incubated for approximately 5 min at 37°C. Once cell detachment was visually 
confirmed, the suspension was transferred to a centrifuge tube and spun down at 1500rpm for 5 
min. The pellet was then resuspended in proliferation medium, and split 1:2 for expansion, or 
seeded onto glass coverslips at the desired cell density. 
2.2.2.2 hCMEC/D3 Cell Line 
hCMEC/D3 is an immortalized human cerebral microvascular endothelial cell line, kindly provided 
by P-O Couraud, (Institut Cochin, France), and its derivation has been previously described 
(Weksler, Subileau et al. 2005). Briefly, human brain tissue was obtained from an adult female 
with epilepsy following the surgical excision of an area of temporal lobe. The tissue was then 
subjected to enzymatic digestion, and microvessel fragments were separated by density-
dependent centrifugation on 25% bovine serum albumin. These fragments were then washed and 
plated onto Type I Collagen coated plastic tissue culture flasks and grown to 50% confluence. 
They then underwent sequential lentiviral transduction of hTERT and SV40 large T antigen, and 
individual transduced cells were separated to produce clonal cell lines. Of these, the D3 line was 
selected based on its endothelial morphology, growth capacity, contact inhibition at confluence, 
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and stable expression of endothelial markers, such as von Willebrand Factor, PECAM-1, β-
catenin and ZO-1. 
For these experiments, D3 cells were grown in T75 tissue culture flasks (BD Biosciences) coated 
with rat tail collagen I (BD Biosciences) at 150µg/ml for 2 hours at 37°C in 5% CO2. Growth 
medium consisted of EBM-2 supplemented as described in Table 2.2, and cells were passaged 
using Accutase (Sigma-Aldrich) when they reached 95% confluence. 
Table 2.2. hCMEC/D3 Medium components 
Component Final Concentration Supplier 
EBM-2 Basal medium Lonza 
Fetal Bovine Serum "Gold" 5% PAA 
Chemically defined lipid concentrate 1% Life Technologies 
Penicillin-Streptomycin 1% Sigma-Aldrich 
HEPES 10mM Sigma-Aldrich 
Ascorbic Acid 5µg/ml Sigma-Aldrich 
bFGF 1ng/ml PeproTech 
Hydrocortisone 1.4µM Sigma-Aldrich 
 
2.2.2.3 Storage and revival 
For cryogenic storage, cells were harvested as for passaging above and cells were resuspended 
in 1ml complete medium with 10% (v/v) DMSO (Dimethyl Sulfoxide, Sigma) at ~5 x 106 cells/ml 
for STROC05, or 5% DMSO at ~1 x 106 cells/ml for hCMEC/D3. The suspension was then 
transferred to a cryovial, which was put into a -80°C freezer in a secondary container (Mr Frosty) 
with isopropanol to ensure slow, steady freezing. After 24 hours, the cryovial was transferred to 
liquid nitrogen. 
To revive cells, the cryovial was removed from storage and placed directly into a 37°C water bath 
until thawed. The suspension was then transferred to 10ml complete medium in order to dilute the 
DMSO, and centrifuged before resuspending the pellet in proliferation medium, seeding into a 
T75 and culturing under normal maintenance conditions. The medium was changed after 12-24 




Cells were rinsed twice with HBSS (Hank’s Balanced Salt Solution, Gibco), then incubated for 15 
min with cold 4% paraformaldehyde (PFA). Cells were then rinsed three times with PBS (0.01M 
Phosphate Buffered Saline, Sigma tablets) before being used for immunocytochemistry, or being 
sealed with Parafilm and stored under PBS + Sodium Azide (0.02%, Sigma) at 4°C for later 
analysis. 
2.2.2.5 Immunocytochemistry 
Coverslips were washed 3 x 5min in PBS. Cells were then incubated for 1 hour at room 
temperature in blocking solution (PBS + 10% Normal Goat Serum, Vector Labs + 0.1% Triton 
X100, Sigma) before being incubated at 4°C overnight with the required antibodies (Table 2.3). 
Cells were then washed again 3 x 5min in PBS before being incubated with AlexaFluor secondary 
antibodies diluted 1:500 in PBS for 1 hour at room temperature. Cells were then washed 3 x 5min 
in PBS before being mounted onto slides in a drop of Vectashield mounting medium + DAPI 
(Vector Labs). 
Visualization of the BrdU label required a 2 step procedure. Immunocytochemistry for any other 
antibodies was performed first, then BrdU staining was applied. For this, cells underwent an 
additional fixation with 4% PFA for 20min to preserve the previous staining after removal of the 
secondary. Sections were then washed 3 x 5min in PBS followed by acid treatment to denature 
the DNA and allow binding of the BrdU antibody. Sections were incubated on ice for 10min with 
1.0M HCl (Hydrochloric Acid, Sigma), then 10min at room temperature in 2.0M HCl followed by 
20min in 2.0M HCl at 37°C. To neutralize the acid, cells were then incubated for 12min at room 
temperature in 0.1M Borate buffer (Sodium tetraborate decahydrate, Sigma) in PBS. Sections 
were then stained with BrdU antibody (rat anti-BrdU, 1:5,000, AbD Serotec) and the relevant 
AlexaFluor secondary according to the protocol above, but the overnight incubation with primary 






Table 2.3 Antibodies and concentrations used throughout in vitro and in vivo immuno-staining. 
Antibody Concentration Company Cat. Ref. 
BrdU 1:5000 AbD Serotec MCA2060T 
Galc 1:300 Millipore MAB342 
GFAP 1:3000 Sigma G3893 
HNA 1:400 Chemicon MAB1281 
HSP27 1:200 Enzo Life Sciences SPA-803 
Ki67 1:500 Abcam ab15580 
Nestin 1:2000 Millipore MAB5326 
Sox2 1:500 Santa Cruz sc-17320 
STEM101 1:500 Stem Cells Inc. AB-101-U-050 
Tuj 1:500 Abcam ab18207 
 
2.2.3 Cell labeling 
Labels were used according to the manufacturers’ instructions, or as previously used for cell 
tracking. This resulted in a range of different conditions and incubation times, shown in Figure 
2.4. PKH26 is highly lipophilic and therefore requires only brief contact with cell membranes for 
intense fluorescence to be seen. Hoechst is highly cell permeant, with a high binding affinity and 
therefore also only requires a short incubation. Some Qtracker staining was observed with shorter 
incubation times, but a longer incubation time provided more homogenous labeling. BrdU is 
incorporated into cells only during DNA synthesis. Since the doubling time of this cell line is 3-4 
days, a 4 day incubation should allow every cell to go through a proliferation cycle, and therefore 
to incorporate BrdU during DNA synthesis. 
 





Cells were labeled according to the manufacturer’s instructions (Sigma-Aldrich). Briefly, cells were 
harvested as for passaging, and the pellet resuspended in 1ml media. Viability (%) was then 
calculated by Trypan Blue exclusion, and the cells re-pelleted. 1ml diluent C per 1 x 106 cells was 
then added to resuspend cells, and an equivalent volume of PKH26 diluted 1:100 in diluent C was 
then added, to give a final concentration of 1:200 (5µM). Cells were then incubated for 4 minutes 
before 1% human albumin solution was added (equivalent volume to cell suspension) and 
incubated for a further 1 minute. Cells were then repelleted and washed three times in DMEM/F12 
before being seeded at the appropriate density onto laminin-coated coverslips. The excitation 
spectrum of PKH26 peaks at 551nm and the emission spectrum at 567nm.  
2.2.3.2 BrdU, 5-Bromo-2’-Deoxyuridine 
77mg BrdU was dissolved in 5ml distilled water to give a 50mM stock solution. This was further 
diluted 1:250 and filtered (0.22µm pore size) to give a 0.2mM working solution. This is added to 
normal culture medium at 1:1000 to give a final concentration of 0.2µM (Caldwell, He et al. 2005) 
and media was replaced twice a day for four days. Cells were then harvested and seeded at the 
appropriate density. BrdU is not intrinsically fluorescent, but is detected using antibodies, so the 
excitation and emission spectra can be selected to match the microscope’s filter sets. 
2.2.3.3 Hoechst 33342 
A stock solution was made up by dissolving 10mg Hoechst 33342 (Sigma) in 5ml distilled water to 
give a 2mg/ml solution, which was then filtered. This was added to normal culture medium at 
1:1000 to give a final concentration of 2µg/ml, which was added to adherent cells for 30 minutes. 
Cells were then washed 3 times with HBSS before being harvested and seeded at the appropriate 
density. Due to the toxicity of Hoechst to this cell line, dilutions down to 0.02µg/ml were tested 




Figure 2.5 STROC05 cells were labeled with different concentrations of Hoechst, and allowed to differentiate 
for 7 days. A similar cell loss (number of DAPI cells) compared to unlabeled cells was observed with all 
concentrations tested. However, endothelial cells did not appear to be affected. Scale bar = 100µm 
 
2.2.3.4 Qtracker 
Qtracker 565 (Life Technologies) was used according to the manufacturer’s instructions. Qtracker 
solution was made up by mixing together the required volumes of components A and B, and then 
incubating for 5min at room temperature. Fresh proliferation medium + 2% human albumin 
(Biosera) was then added to give a final Qtracker concentration of 15nM, and the solution was 
vortexed for 1min. Adherent cells were then washed twice with DMEM:F12, Qtracker solution was 
added, and cells were incubated for 24h at 37°C. Cells were then washed twice with DMEM:F12 
and fresh proliferation medium was added, incubating at 37°C for 2.5h before harvesting as 
normal. The excitation spectrum of Qtracker 565 peaks below 400nm and the emission spectrum 
peaks at 565nm. 
2.2.3.5 Fast Blue 
Protocol 1 (Pettersson, Lobov et al. 2010): A 20mg/ml aqueous solution of fast blue (Sigma) was 
prepared, and 5µl was added to a 1ml suspension of 1 x 106 cells to give a final concentration of 
100µg/ml. This was incubated at 37°C for 15 minutes before seeding cells at the appropriate 
density. This method resulted in very low cell survival, which was thought to be due to mechanical 
damage from particulate matter to the cell membranes during pipetting in suspension. It was 
therefore hypothesised that labeling cells as a monolayer may improve survival so the following 
method was tested 
Protocol 2 (Liudmila Novikova, Umeå University): Culture medium was removed from growing 
cells and fresh culture medium was added containing fast blue at 5µg/ml. Cells were incubated for 
12 hours before fast blue was removed and cells washed five times in DMEM/F12 before being 
harvested and seeded at the appropriate density. At this concentration, cell survival was not 
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affected, but no fast blue labeling was seen. Concentrations of 20, 40, 60. 80 and 100µg/ml were 
therefore tested using Protocol 2, and the number of surviving cells after 24 hours was counted 
using a ToPro3 (Invitrogen) nuclear counterstain (Figure 2.6). Cell survival decreased with 
increasing concentration of fast blue, but no labeling was seen at any concentration. Fast Blue 
was therefore excluded from further experiments. 
 
Figure 2.6. Fast Blue affected cell survival in a dose dependent manner, and no positive fast blue staining 
was seen even at the highest concentration. Scale bar = 100µm. 
 
2.2.3.6 Enhanced Green Fluorescent Protein (eGFP) 
Generation of eGFP-STROC05 cell line was performed by Dafe Uwanogho using lentiviral 
transfection of eGFP under a UCOE (Ubiquitous Chromatin Opening Element) promoter, 
designed to resist silencing in vivo. Once transduced, the eGFP cell line was cultured and 
passaged using the standard protocol. 
eGFP expression was successfully detected (Figure 2.7A within 100% of cells. The 
intensity of the fluorescence was variable across the population. Cells were stained for Ki67 as a 
marker of proliferation at day 1 and 7, and the proportion of cells expressing Ki67, as well as the 
total cell number (DAPI+) were counted (Figure 2.7B). There were many more GFP+ cells 
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present than controls at both day 1 and after 7 days differentiation (Figure 2.7C). This can be 
accounted for by a dramatic increase in proliferation, as Ki67 was expressed by close to 98% of 
eGFP+ cells at day 1, compared to 55% of controls (Figure 2.7D, p<0.001). Additionally, cells 
appeared to be morphologically very different (Figure 2.7E), with a loss of processes and an 
increase in cell density. However, this difference appears to have been induced by the infection 
process itself rather than the presence of eGFP protein, as cells transduced by the empty vector 
showed the same morphological change. This eGFP+ cell line was therefore not taken forward for 
further experiments, particularly since the high rate of proliferation suggests potential 
tumorigenicity in vivo. 
 
Figure 2.7 Effects of transduction on STROC05 NSCs. eGFP expression was robust (A), but cells stained 
with DAPI and Ki67 (B) showed a large increase in cell number compared to controls (C). Ki67 was 




2.2.4 In vitro assays 
2.2.4.1 Cell Viability 
Trypan Blue Exclusion: Trypan blue dye is excluded from viable cells with an intact membrane, 
which therefore remain uncoloured, whereas dead or dying cells are permeable to the dye and 
become stained blue. Directly after completion of the labeling protocol, cells were harvested if 
necessary. Equal amounts of cell suspension and Trypan blue solution were thoroughly mixed by 
pulsing 10x with a pipette. The resulting suspension was transferred to a haemocytometer, and 
two counts were taken – total cells (Total), and blue stained cells (Blue). This was then expressed 
as a percentage: (Total - Blue)/Total x 100 = percentage viable cells 
Live/Dead: Live/Dead staining was carried out using the LIVEDEAD cytotoxicity/viability kit 
(Invitrogen). Cells were simultaneously stained with green fluorescent calcein-AM (intracellular 
esterase activity) indicating a viable cell and red ethidium homodimer-1 (EthD-1) indicating a loss 
of membrane integrity evident in dead or dying cell. For this, cells were seeded at 1 x 105 
cells/well on 13mm glass coverslips (VWR, laminin coated as for flasks above) in 24 well plates, 
in proliferation medium (Table 2.1), and cultured for 24 hours at 37°C. A solution was made up 
with PBS containing 4µM EthD-1 (component B; 20µl/10ml PBS) and 2µM Calcein AM 
(Component A; 5µl/20ml) and vortexed for 30 sec. 300µl of this solution was added to live cells 
after removal of media, and this was incubated at room temperature for 30 min in the dark. Slides 
were prepared by drawing circles using a hydrophobic barrier pen (DAKO) and dropping ~50µl of 
PBS into the centre. Coverslips were then placed cells-down onto this solution to avoid drying 
during imaging. Imaging was carried out immediately, using consistent exposure times to allow 
comparison between images. The excitation wavelength used for EthD1 also excited PKH26 due 
to their similar properties, but viable PKH26-labeled cells could still be distinguished by the 
additional green Calcein AM. 
2.2.4.2 Cell survival & Proliferation 
After labeling, cells were harvested if necessary and seeded at 1 x 105 cells/well. They were then 
cultured for 24h in proliferation medium. Cells for the Day 1 time point were then fixed, while cells 
for the day 7 time point were transferred into differentiation medium (Table 2.1) and cultured for a 
further 7 days before being fixed. 
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All cells were assayed for cell number by counting the total number of DAPI stained nuclei over 9 
fields of view per coverslip (445x335µm, 20X objective). To measure proliferation, cells were 
stained for Ki67, which is present in the cell nucleus during all active phases of the cell cycle, only 
being absent during G0 phase. The number of Ki67 cells was expressed as a percentage of DAPI 
nuclei, giving the percentage of cells proliferating. 
2.2.4.3 Differentiation 
After labeling, cells were harvested if necessary and seeded at 1 x 105 cells/well. They were then 
cultured for 24h in proliferation medium. Cells for the Day 1 time point were then fixed, while cells 
for the day 7 time point were transferred into differentiation medium as above and cultured for a 
further 7 days before being fixed. 
Proliferation medium was then removed, cells were rinsed once with DMEM:F12 and 
differentiation medium was added (Table 2.1). The differentiation medium was changed after 30 
min to improve removal of residual growth factors, and every other day thereafter. 
After 7 days in differentiation medium, cells were fixed and stained with GFAP (Glial Fibrillary 
Acidic Protein, a marker of astrocytic lineage), Tuj1 (Neuronal class III beta-tubulin, a marker of 
early neuronal lineage) and Galc (Galactocerebroside, an oligodendrocyte marker). The number 
of cells staining positively for these markers was expressed as a percentage of DAPI+ cells, 
counted over 5 fields of view per coverslip, and was compared to unlabeled STROC05. 
2.2.4.4 Co-cultures 
In order to assess label leakage in vitro, NSCs were labeled, cultured overnight, and then mixed 
with unlabeled endothelial cells (1:1 ratio) in suspension before seeding the mixture into wells. 
Coverslips were coated with a mixture of collagen 1 as used for routine culture of endothelial 
cells, and laminin as used for culture of NSCs. The medium for the two cell types was also mixed 
in a 1:1 ratio. After 24 hours, cultures were stained for nestin, which is present in NSCs, but not 
ECs. Therefore co-localisation of nestin and the tested label indicates correct identification, 
whereas the presence of the label in a nestin negative cell indicates label leakage.  
In order to rule out the possibility that observed results were only due to mechanical transfer 
between cells during the pipetting process, other paradigms were investigated. Figure 2.8A 
shows the method as described above. In Figure 2.8B, ECs are seeded first and cultured for 24 
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hours in their normal medium before switching to mixed media and seeding labeled NSCs on top. 
In Figure 2.8C, labeled NSCs are seeded first and cultured for 24 hours in their normal medium, 
before being washed three times with HBSS, switching to mixed media and seeding ECs on top. 
Finally, ECs and labeled NSCs were cultured separately for 24 hours in their own medium, before 
the conditioned medium from the NSCs was added to the ECs (Figure 2.8D), which were cultured 




Figure 2.8. Conditions tested for co-culture, shown here with PKH26 labeled cells. Labeled NSCs (staining 
positive for nestin, green) were seeded with unlabeled ECs and co-localisation of PKH26 with nestin was 
assessed 24 hours later. Results were unaffected by seeding conditions. Whether labeled and unlabeled 
cells were seeded together (A), unlabeled cells were seeded first (B), labeled cells were seeded first (C) or 





The way in which cells are prepared for transplantation can affect their in vivo survival. 
Additionally, transplantation of dead cells is known to have effects on label leakage and reuptake 
(Burns, Ortiz-Gonzalez et al. 2006), making consistent cell viability at transplantation vital for this 
study. Conditions for storage of cells between cell preparation and transplanted were therefore 
tested, comparing room temperature against ice over time to define the available time window at 
each condition. Cells were prepared as for transplant at 50,000 cells/µl on three separate 
occasions, and three samples were counted at each time point. Cells maintained their viability 
much better at room temperature than when stored on ice, with a time window of 7 hours after 
preparation (Figure 2.9), so these were the conditions selected for use prior to in vivo 
experiments. 
 
Figure 2.9. Cell storage conditions between preparation and transplant. Cells stored on ice after preparation 
showed a reduction in cell viability after 4 hours compared to immediately post preparation (blue line, 
p<0.05). However, when cells were stored at room temperature, their viability remained consistent up to 7 
hours (red line, p=0.097). Data are shown as median ± range, (n=9). 
 
2.2.5.1 Cell Preparation 
Cells were labeled the day before transplantation, and incubated overnight in fresh proliferation 
medium based on results showing that overnight incubation after labeling reduced in vivo leakage 
(Lassailly, Griessinger et al. 2010). They were then washed three times with HBSS before being 
harvested as normal and resuspended in PBS. Cells were then counted (6 samples) using a 
haemocytometer and the total number of cells in the suspension was calculated. Cells were then 
centrifuged (5min, 1500rpm) and PBS aspirated. In order to achieve a cell density of 50,000 
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cells/µl, the volume of PBS to be added was calculated taking into account the cell volume as 
follows: 
VL = VT - VC 
Where VL = the volume of liquid to be added; VT = Total volume of suspension (µl) = Total cell 
number/50,000; VC = Volume occupied by cells = Total cell number x 3.912pl (volume of 1 cell) 
Worked example: 
For a total of 3x106 cells, VT = 3x106/50,000 = 60µl and VC =  3x106 x (3.912x10-6) = 11.7µl. 
Therefore the volume of PBS to be added = 60 - 11.7 = 48.3µl 
The cell density was then verified by diluting 1µl of cell suspension in 50µl PBS and then further 
diluting 1:2 in Trypan Blue before counting (n=6 samples) using a haemocytometer, and 
adjustments made if the density was more than 10% different from the target density. For a target 
density of 50,000 cells/µl, densities of 45,000 to 55,000 cells/µl and cell viability of >85% were 
accepted (Figure 2.10). Cells were then aliquoted into separate suspensions for each animal to 
minimise potential variation and loss of viability induced by repeated resuspension. 
 
Figure 2.10. Cell density (A) and viability (B) with mean for each label. The range indicates the variation 
between different sets of transplant surgeries. Dotted lines show cut-off points. 
 
2.2.5.2 Stereotactic Surgery 
Male Sprague-Dawley rats (180-200g, Taconic Labs) were kept on a 12 hour light/dark cycle and 
allowed food and water ad libitum. Animals were then anesthetized using Isoflurane (4% 
induction, 2% maintenance) and secured to the stereotactic frame (Kopf) using ear and teeth 
bars. Body temperature was maintained using a homeothermic heating blanket controlled by a 
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rectal temperature probe. A rostro-caudal incision was made along the top of the head, and 
Bregma was located. A frame-mounted drill was used to make small burr holes in the skull at 
0.9mm anterior and ±2.5mm laterally to Bregma. Cell suspension was briefly pipetted to 
resuspend cells, and 5µl of cell suspension was then taken up into a 10µl Hamilton syringe. For 
each set of surgeries, separate syringes were used for each group to avoid cross contamination, 
and each syringe and needle were cleaned 3 times in 3 separate vials of sterile PBS between 
animals. The syringe was then attached to the frame, and the 26G needle was inserted slowly to 
5.5mm below dura. 4µl of cell suspension (total ~200,000 cells) was then injected at 1µl/min, and 
the needle was left in place for an additional two minutes before being slowly removed. Each 
animal received two injections (different experimental groups), one in each hemisphere. The two 
burr holes were then sealed with bone wax (Fisher), the incision was sutured, and the animal was 
given topical analgesic cream (2.5% Lidocaine and 2.5% Prilocaine, Sandoz) and IP Buprenex 
(0.05mg/kg; Henry Schein) and allowed to recover. Animals were then weighed daily until they 
had regained their pre op weight. 
2.2.5.3 Perfusion 
Animals were given IP injections of Pentobarbital Sodium (Fatal Plus, Vortech) at 10mg/100g 
body weight, and observed until the righting reflex was absent. They were then placed in a supine 
position inside a chemical hood, and the toe pinch reflex was tested. Once this was absent, the 
rib cage was dissected until the heart was easily accessible. The descending aorta was clamped, 
and a needle placed through the bottom of the left ventricle, and into the aortic arch, where it was 
clamped in place. The right atrium was then cut to allow exsanguination, and the peristaltic pump 
(MasterFlex, Cole Parmer) connected to the needle was switched on to pump ice cold PBS 
(0.01M) through the system. Once the outflow began to run clear, the pump was switched to ice 
cold PFA (4% in 0.01M PBS). Perfusion was concluded when the animal’s forearms became rigid, 
and the brain was then removed and placed in 4% PFA overnight, after which it was washed 
three times in PBS and placed into 30% Sucrose (Sigma) for cryoprotection in PBS with 0.5% 
Sodium Azide for preservation.  
2.2.5.4 Sectioning 
Brains were separated into two hemispheres, embedded in frozen section compound (Surgipath 
FSC 22, Leica) and cut at 40µm section thickness 1:8 series on a Leica Cryostat. These were 
60 
 
then stored as floating sections in Tissue Cryopreservation Solution (TCS, 30% Ethylene Glycol, 
25% Glycerol and 0.5% Sodium Azide in PBS) to prevent freezing at -20°C until processing for 
Immunohistochemistry. 
2.2.6 Immunohistochemistry 
Immunohistochemistry was performed as in section 2.2.2.5 for immunocytochemistry. Floating 
sections were transferred from one wash to the next in a 24 well plate using a paintbrush. 
Additionally, all washing and incubation steps were carried out on a shaker, and 0.3% Triton X-
100 was used, rather than 0.1%. These measures were taken in order to improve antibody 
penetration of the tissue. 
Instead of using Vectashield + DAPI, sections were incubated for 5min on a shaker at room 
temperature with Hoechst (1µg/ml in PBS, Sigma) before being washed again (3 x 5min, PBS), 
mounted onto slides and coverslipped with Vectashield mounting medium (Vector Labs). This 
again improved homogeneity of staining throughout the tissue thickness. 
2.2.7 Image analysis 
Images for analysis were acquired using an AxioImager M2 microscope (Zeiss) in conjunction 
with Stereo Investigator software (MBF). In one series, all areas containing cells positive for HNA 
or for the label of interest were imaged using a 20X objective. For analysis, alternate sections of 
those imaged were selected in addition to always choosing the first, last and centre section 
containing cells in order to have a representative coverage of the graft. In each image, an ROI 
was drawn and all cells within it that were positive for HNA and/or label of interest were counted 
and categorised using ImageJ64 and its cell-counter tool. Cells (Hoechst+) were categorised as 
“correctly identified” where both HNA and the label were present, “false negative” where HNA was 
present but the label was not, or “false positive” where HNA was not present but the label was. 
Cells with faint, shadowy HNA staining that expanded well beyond the nucleus were not counted 
as HNA positive, as this was background auto fluorescence. Cells with cellular HNA staining were 
counted as positive, whether the staining was nuclear or cytoplasmic. An indicator of positive 
Qtracker and PKH26 labeling is concentrated dots around the nucleus and, in the case of BrdU, 
labeling of the nucleus. Extremely bright flares of fluorescence were not counted as this is not 





Figure 2.11. In vivo quantification. ✓ indicates a cell correctly identified by the label, positive for both HNA 
and the label under investigation (here BrdU). + indicates a false positive, where an HNA negative cell is 
positive for BrdU. –	 indicates a false negative, where a cell is positive for HNA but negative for label. * 
indicates fluorescent debris, which was not counted as positive BrdU staining. O indicates cells negative for 
both HNA and BrdU which would therefore not have been included in the count. Scale bar = 100µm. 
 
2.2.8 Statistics 
Statistical tests were performed using Prism 5.0f (GraphPad). Where percentages are calculated 
and the values are close to 0 or 100%, there is potential for the distribution to become skewed 
due to floor or ceiling effects. Therefore, normal distributions have not been assumed, and non-
parametric tests have been used throughout. For cell viability over time (Figure 2.9), a Friedman 
test was used, with Dunn’s multiple comparison test. For all other in vitro experiments, Mann-
Whitney tests were used to compare each group of labeled cells with its matching control. For in 
vivo analyses (Figure 2.18), Kruskal-Wallis tests were used with Dunn’s multiple comparison test 
to compare all labels to each other. Values were considered significant where p<0.05. For in vitro 
assays, three biological replicates, each with three technical replicates were conducted to give 





2.3.1 Cell labeling 
From the six labels under investigation here, Fast Blue did not label cells and hence was omitted 
from further analysis. eGFP labeled the cells, but was also excluded from further analysis due to a 
significant transformation in cellular characteristics. The four labels that were advanced for further 
testing were Hoechst, BrdU, PKH26 and Qtracker. All were easily incorporated into STROC05 
NSCs. Hoechst is seen in the nucleus, co-localised with ToPro3, used here as a nuclear 
counterstain during immunocytochemistry. BrdU is also localised to the nucleus, whereas PKH26 
and Qtracker are both situated in the cytoplasm, shown by their co-localisation with nestin (Figure 
2.12A). Hoechst showed a very homogenous distribution across cells (Figure 2.12B), with all 
showing approximately equal fluorescence. BrdU, however, was highly variable with some cells 
fluorescing much more brightly than others. PKH26 and Qtracker appear similar, and both are 
somewhat variable across the population. 
The expected intracellular localisation of each label is shown in Figure 2.12C. Hoechst binds to 
the minor groove of DNA, whereas BrdU is incorporated into DNA during proliferation, replacing 
Thymidine. These localisations are both corroborated by the cell images shown. PKH26 binds to 
the phospholipid bilayer, inserting into the cell membrane and was therefore expected to be 
mainly at the edge of the cell. However it is seen in the perinuclear area, suggesting incorporation 
into the membranes of organelles and endosomes. The Qtracker system is based on Qdot 
nanocrystals at 10-20nm, consisting of a core made of cadmium mixed with selenium or tellurium, 
coated with zinc sulphide. This is coated with a proprietary targeting peptide for localisation to the 
cytoplasm, which is reflected here by the location of the intracellular fluorescence.  
All labels showed over 99% labeling efficiency at day 1 (Figure 2.12D). There were insufficient 
Hoechst labeled cells remaining at day 7 for analysis. BrdU showed a significant drop in labeling 






Figure 2.12. Label Efficiency. The appearance of cells after labeling is shown here at the single cell level 
(A), and the population level (B). The intracellular localisation of each label is slightly different (C). Labeling 
efficiency was high at day 1 for all labels tested (D). At day 7, efficiency remained high for PKH26 and 




2.3.2 Cell viability 
In order to assess the effects of the labels on cell viability, Trypan Blue and Live/Dead assays 
were used to count the number of live and dead cells (Figure 2.13A). The Trypan Blue exclusion 
assay consists of a blue dye which is only cell permeable when the cell membrane is damaged. 
Therefore the number of cells able to exclude the dye as a proportion of the total gives a measure 
of the number of viable cells. No significant difference was shown from controls immediately after 
labeling for Hoechst, BrdU or Qtracker labeled cells (Figure 2.13B). However, PKH26 labeled 
cells showed a significant 6.4% reduction in viability (p<0.001). This shows that the labeling 
procedure for PKH26 affects viability, although whether the source is the label itself or other 
causes (e.g. supplied diluent, labeling in suspension) remains unclear. Additionally, since 
Hoechst, BrdU and Qtracker labeling protocols are all conducted on adherent cells, there is 
opportunity for dead cells to detach and be lost during the labeling procedure, and therefore not 
be included in the final count. 
The Live/Dead assay consists of red dye permeable only to cells with a damaged membrane, and 
also a green dye requiring active intracellular esterases to produce green fluorescence. At 24 
hours after labeling, there were no significant differences from unlabeled cells (Figure 2.13B). 





Figure 2.13. Labeled cells were stained with a Live/Dead kit comprising Calcein AM (green, live cells) and 
EthD1 (red, dead cells, A). Viability of labeled cells was compared to control cells using Trypan Blue 
immediately after labeling and Live/Dead after 24 hours (B, median change in % viability). Scale bar = 
100µm 
 
2.3.3 Cell survival and proliferation 
In order to gauge delayed effects on cell death and proliferation, cells were seeded onto 
coverslips and allowed to proliferate overnight or differentiate for one week before being fixed, 
and the number of remaining cells counted. Cells were then stained for Ki67, a marker of 
proliferation (Figure 2.14A). The cell number and percentage expressing Ki67 were compared to 
unlabeled cells, to provide a measure of the changes induced by the label.  
Hoechst had the most dramatic effect on cell number (Figure 2.14B), with 77% fewer cells than 
controls at day 1 (p<0.01), and almost no cells remaining at day 7 (p<0.001). Ki67 expression was 
also reduced by 45% (p<0.001) at day 1, and there were insufficient cells to assess this at day 7. 
Hoechst was therefore not taken forward to further in vitro or in vivo testing. 
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BrdU had the smallest effect on these parameters (Figure 2.14C). Proliferation is slightly elevated 
at day 1 at 12.8% higher than controls (p<0.05), but there was no significant change in cell 
survival (p=0.095). By day 7, there appears to be very little difference to control cells (Survival 
p=1.0; Ki67 p=0.72), showing no delayed toxicity due to the presence of the label within cells over 
7 days.  
Cells labeled with PKH26 appeared different from controls at day 1, but similar at day 7 (Figure 
2.14D). At day 1, cell number was elevated (p<0.001) while Ki67 expression was lower than 
controls (p<0.001). Since the expression of Ki67 is reduced, the high cell number at day 1 is not 
likely to be due to an increased proliferation rate. It may therefore be due to improved adhesion or 
survival of cells after plating, as passaging of unlabeled STROC05 cells normally results in some 
cells floating and being lost in media changes rather than adhering to the laminin coating. 
However, at day 7 neither cell number (p=0.93) nor Ki67 expression (p=0.37) are different to 
controls. The return of cell number to normal levels can be accounted for by the reduced 
proliferation rate seen at day 1. It seems that the labeling process itself rather than the presence 
of the label may be the source of the change in cell behaviour at day 1.  
Cells labeled with Qtracker showed an increased cell number at both time points, whereas Ki67 
expression was elevated at day 1 and then slightly reduced at day 7 (Figure 2.14E). The cell 
number at day 1 was more than double (124%) that of controls (p<0.001), whilst Ki67 expression 
was only slightly elevated (27% higher than controls, p<0.0001). Given that the doubling time of 
these cells is 3-4 days, it seems unlikely that the modest increase in proliferation could be solely 
responsible for the large increase in cell number over just one day. It is therefore likely that cell 
survival and/or adhesion are also enhanced by Qtracker or the labeling protocol during the 
passaging process. However, the specifics of the targeting peptide used in the Qtracker kit are 
unavailable so its potential interactions remain unclear. At day 7, cell number remains significantly 
higher than controls (p<0.001), but this is likely to be a direct result of the higher cell number at 
day 1, and therefore does not represent any further change. However, Ki67 expression is reduced 





Figure 2.14. Effects of labels on STROC05 survival (DAPI+ cells) and proliferation (Ki67 expression) (A). 
Hoechst showed the most dramatic effect, with very few cells remaining at day 7 (B). BrdU showed little 
difference from controls, suggesting that the label is well tolerated (C). PKH26 showed differences at day 1, 
but not at day 7 (D), and Qtracker showed differences at both time points, showing that cells were affected 
by the label’s presence in the cell (E). Scale bar = 100µm. 
 
2.3.4 Label effects on cell phenotype 
In order to assess more subtle effects on the biology of neural stem cells, labeled cells were 
differentiated for seven days before being stained for markers of different lineages; GFAP for 
astrocytes, Tuj for neuronal cells and Galc for oligodendrocytes (Figure 2.15A). Tuj and Galc 
positive cells appear morphologically consistent between control and labeled cells. However, 
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clear differences can be seen in GFAP positive cells. Compared to controls, PKH26 labeled 
GFAP+ cells show morphology more characteristic of reactive astrocytes, with increased 
projections and brighter staining. Qtracker GFAP+ cells, however, show long single or double 
projections rather than multiple ones, more suggestive of a radial glia phenotype. 
Cells labeled with BrdU have a lower proportion of GFAP positive cells at both 1 day (p<0.05) and 
7 days (p<0.05, Figure 2.15B). Since the difference between labeled and unlabeled cells remains 
consistent between day 1 and day 7, it seems that this is due to initial toxicity of the BrdU labeling 
protocol to GFAP positive cells, and that the continued presence of the label in the cell does not 
have further effects. The number of Tuj positive cells is not significantly different from controls 
either at day 1 (p=0.86) or day 7 (p=0.64), showing that BrdU does not affect the proportion of 
neuronal precursors. The number of Galc positive cells is significantly higher than controls at day 
1 (+18%, p<0.01), suggesting that these might be the cell sub-population with increased 
proliferation. At day 7, the difference is smaller but still significant (+6%, p<0.01), consistent with 
reduced proliferation. 
PKH26 labeled cells do not show significant differences for any of the three markers at day 1 
(GFAP p=0.16, Tuj p=0.93, Galc p=0.10, Figure 2.15C), showing that the labeling process does 
not have acute effects on cell phenotype. However, the presence of the label in cells over 7 days 
shifts the ratio of cell populations towards GFAP positive cells, with an 11% increase in GFAP 
positive cells (p<0.001), but a decrease in Tuj positive (-6%, p<0.001) and Galc positive (-3.6%, 
p<0.05) cells. 
Qtracker labeled cells show a significant increase in the proportion of GFAP positive cells at day 1 
(p<0.001) and day 7 (p<0.001, Figure 2.15D), showing that the labeling process increases this 
proportion, but that the continued presence of the label does not appear to have further effects. 
The proportion of Tuj positive cells is not significantly different from controls at day 1 (p=0.81) or 
day 7 (p=0.063). The proportion of Galc expressing cells is not significantly different from controls 




Figure 2.15 Cells were allowed to differentiate over seven days and stained for GFAP, Tuj and Galc (A). The 
percentage of cells expressing each marker was compared to unlabeled cells after labeling (median % 
change) with BrdU (B), PKH26 (C) or Qtracker (D), and are show here as median change from controls. 
Scale bar = 100µm. 
 
2.3.5 Label leakage in vitro 
In order to assess the propensity for the label to be released from labeled cells and taken up by 
its neighbours, labeled NSCs were seeded together with unlabeled D3 endothelial cells (ECs). 
These were distinguishable by staining with an antibody against nestin or sox2, which are 
expressed by NSCs but not ECs. Therefore label retention could be assessed on its localization 
within only nestin or sox2 positive cells. 
With Hoechst-NSCs, all ECs were Hoechst positive after 24 hours (Figure 2.16A). Although the 
DNA binding of this label makes it less likely to be lost from viable cells, Hoechst labeling has a 
significant effect on viability. It’s therefore likely that the label was released from dying cells and 
taken up by those remaining. With BrdU-NSCs, some ECs remained unlabeled (Figure 2.16B, 
red arrow), but some were faintly labeled with BrdU (Figure 2.16B, blue arrow). This reflects the 
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higher cell survival of BrdU-NSCs compared to Hoechst-NSCs, and that its incorporation occurs 
only during DNA synthesis. With PKH26-NSCs, all ECs were labeled after 24 hours (Figure 
2.16C). Similar lipophilic dyes DiI and DiR have previously been shown to be released not freely 
into media but in diffusible elements recoverable by ultracentrifugation (Lassailly, Griessinger et 
al. 2010). These data show that PKH26 is transferable by the same mechanism, as conditioned 
medium was sufficient to induce EC labeling (see section 2.2.4.4). This mechanism is most likely 
exosome transfer, which has been shown to occur in neural progenitor cells (Marzesco, Janich et 
al. 2005). Qtracker-NSC co-culture also resulted in labeling of all ECs, and are also likely to be 
transferred within exosomes due to their cytoplasmic location. Overall, BrdU was the only label 
not to result in labeling of 100% of co-cultured ECs, but some label transfer was still observed. 
 
Figure 2.16 Labeled NSCs were seeded with unlabeled ECs to assess label transfer. All cells are stained 
with nuclear counterstains ToPro3 (A, red) or DAPI (B,C,D, blue). NSCs can be identified by nestin (A,C,D, 
green) or sox2 staining (B, red). Green arrows show labeled NSCs; Blue arrows show labeled ECs, 
indicating that label has been transferred from NSCs. Red arrow indicates unlabeled ECs. Scale bar = 
100µm. 
 
2.3.6 Reliability of labels for identifying transplanted cells in vivo 
Labeled cells were transplanted into the striatum of healthy rats, and sections were stained with 
HNA (Human Nuclear Antigen) which reacts with the transplanted cells but not host tissue. The 
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extent of co-localisation with HNA was then assessed for each label to give a measure of its 
reliability. The graft appears to be much reduced in size over seven days (Figure 2.17) showing 
that many cells died. However despite this, there does not seem to be significant leakage of the 
labels into surrounding host tissue. Due to the punctate nature of their labeling, PKH26 and 
Qtracker labeled grafts appeared somewhat hazy under the microscope, and at times making it 
more difficult to precisely identify which cell nucleus the labeling belonged to. BrdU as a nuclear 




Figure 2.17 Transplanted cells 1 and 7 days post transplant showing HNA (green), Hoechst counterstain 
(blue) and labels (red). The overall appearance of the graft is consistent across labels at each time point, 
and the size of the graft appears much reduced by day 7. Scale bars = 200µm. 
 
Cells were counted and categorised as either correctly identified (HNA+/Label+), False negative 
(HNA+/label-) or false positive (HNA-/Label+) as shown in Figure 2.18A. At day 1, all labels 
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correctly identified ~60% of cells (Figure 2.18B) with no significant difference between them 
(p=0.99). At day 7, Qtracker correctly identified 75% of cells. This was significantly more than 
PKH26 at 51% (p<0.05). BrdU correctly identified 62% of cells at day 7, which was not 
significantly different from either PKH26 or Qtracker. 
At day 1, ~38% of cells were not identified by the labels, despite being HNA+ (Figure 2.18C), and 
there were no significant differences between the labels (p=1.0). At day 7, PKH26 had 46% false 
negatives, significantly higher than Qtracker at 24% (p<0.05). BrdU was not significantly different 
from either at 29%. 
False positives, where cells appeared to be labeled despite being negative for HNA, constituted 
the smallest group, showing very little transfer of the labels from transplanted to host cells (Figure 
2.18D). At day 1, Qtracker had 1.6% false positives, significantly more than BrdU at 0.16%, and 
PKH26 was not significantly different from either at 0.44%. At day 7 there were no significant 





Figure 2.18 Cells were categorised as correctly identified (HNA+/Label+), False negative (HNA+/label-) or 
false positive (HNA-/Label+) (White arrows, A). The number of cells in each category was counted, and 
expressed as a percentage of the total, shown here as median and IQ range for each label for Correct 




Reliable cell identification is vital in order to understand and improve therapeutic transplants. Here 
we compared widely used cell labels for tracking transplanted neural stem cells. None of the 
labels tested showed significant leakage in vivo, but all showed a large number of false negatives. 
All labels tested showed some effect on cell biology, and the commonly used toxicity tests were 
insufficient to detect these effects. 
2.4.1 Reliable Identification of transplanted cells 
The reliable identification of transplanted cells is essential in order to elucidate their therapeutic 
mechanisms, and the use of exogenous labels is necessary where transplanted cells are not 
immunohistochemically different from host tissue, for example in the case of allo- or auto-grafts. 
Exogenous labels potentially provide a method of identification that is quick, and easy to translate 
between different cell lines and types. Concerns have been raised about their reliability, and most 
of the labels tested here have previously been shown to be transferred to host cells, or otherwise 
to be easily confused with host cell types (Iwashita, Crang et al. 2000, Burns, Ortiz-Gonzalez et 
al. 2006, Lassailly, Griessinger et al. 2010, Spitzer, Sammons et al. 2011). However, they are still 
used and relied upon for identification of transplanted cells, and to draw conclusions about their 
fate (Liu, Zou et al. 2014).  
False negatives have not been studied in much detail, but are equally important. Since labels are 
likely to be lost most quickly from cells that are proliferating, this can induce a bias in drawing 
conclusions about the transplanted population, as a proliferating subpopulation would be 
excluded from the analysis. The concentration of the agent is likely to be a key factor in attaining 
a balance between false positives and false negatives, and factors such as the cell proliferation 
rate in vivo, the time between labeling and transplant and the status of the cell at implantation will 
all affect this optimisation.  
It has previously been shown that transplantation of dead cells results in a higher incidence of 
label transfer (Burns, Ortiz-Gonzalez et al. 2006), showing that the viability of the transplant will 
affect not only its therapeutic efficacy but also the reliable identification of the cells. This 
combination would make interpretation extremely challenging. Factors potentially affecting 
viability here include the storage conditions between cell harvesting and transplant, as well as the 
time window available (Gobbel, Kondziolka et al. 2010). This is particularly important when one 
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cell preparation is used for a number of contiguous surgeries to ensure delivery of a consistent 
product between the first and last transplant of the day (see Figure 2.9). Additional items to 
consider here include those involved in the delivery process, such as potential cell damage if they 
must be delivered through a small bore needle (Agashi, Chau et al. 2009, Gobbel, Kondziolka et 
al. 2010). However, even after transplantation, membrane turnover and vesicle release will cause 
some leakage of labels located in the membrane or cytoplasm (Lassailly, Griessinger et al. 2010). 
Additionally, since the eventual fate of most transplanted cells is cell death (Smith, Stroemer et al. 
2011), a lot of label will eventually be released regardless of the efficiency of its binding to cell 
components.  
2.4.2 Impact of exogenous labels on cell function 
All labels tested here have been previously shown to be both toxic and non-toxic, depending on 
the cell type and labeling protocol (including concentration). This has made it challenging to draw 
comparisons between labels. Additionally, some studies use viability assays as the sole measure 
of label impact, and these have here been shown not to be sensitive to delayed cellular effects.  
The reported phenotypic effects of exogenous labels vary widely, and include proliferation, 
migration, homing and differentiation. One potential mechanism for altering the phenotype of a 
population is through selective toxicity, whereby the viability of a sub-population is affected, 
thereby biasing the proportion of the remaining population towards an alternate phenotype. BrdU 
in particular has been shown to be selectively toxic to neuronal precursors (Caldwell, He et al. 
2005), although this effect can be attenuated by using a lower concentration.  
However, there appear to be other phenotypic effects unrelated to toxicity. In Figure 2.15, a clear 
difference in morphology can be seen between the PKH26- and Qtracker-labeled GFAP+ cells. 
Such a consistent population-wide change in morphology cannot simply be due to selective 
toxicity, and suggests that labels are interfering with cellular pathways. 
When assessing a label’s suitability for use, it is therefore important to take into account the 
proposed therapeutic mechanism. For example where the end goal is tissue replacement, 
differentiation and survival are the most important parameters. However, if neurotrophic effects 
were the proposed mechanism, then ELISAs to assess changes in growth factor release would be 
more important. However, due to the interplay between these with regards to both the transplant 
and host tissue, an extensive battery of tests would be required to rule out label effects. Although 
77 
 
a reasonably high-throughput battery could be set up to encompass a wide range of potential 
effects, this would not be a time- or cost-effective solution for most laboratories. Therefore for 
each labeling application, the utility of the label versus other methods must be weighed against 
the assays required to show a lack of label effects on cell function. 
2.4.3 Future use of exogenous labels 
The results shown here, taken along with previous studies, suggest that where 
immunohistochemistry can be used to identify transplanted cells, that would be preferable to 
using any kind of labeling. However, this is not always possible. Xenografts provide an easy way 
to distinguish between transplanted and host cells, but are not always the preferred paradigm. 
Indeed, they bring extra problems of their own in the form of immunocompatibility issues requiring 
immune suppression. Additionally, not all protein structures are so highly conserved that cells of 
any mammalian species can be transplanted into any other with the same results. Allografts 
therefore have distinct advantages, and with the advent of widely available iPSC technology, 
autografts may become more commonplace. In these instances, there may be no antibody-
detectable differences between transplanted and host cells, necessitating the use of an 
exogenous marker. Additionally, in the tissue engineering field, transplants are becoming 
increasingly complex and may require transplantation of more than one cell population. This again 






Rigorous testing of histological labels is of great importance, particularly as much is yet unknown 
about the therapeutic mechanism of transplanted cells. Simple viability assays are not sufficient to 
reveal the complete nature of a label’s effects on cell biology. All labels tested here showed some 
effect on NSC proliferation and differentiation, indicating that caution should be exercised in their 
use with this cell type. In vitro co-culture showed high levels of label leakage and as such was a 
poor predictor of in vivo reliability, where false negatives were a more significant problem than 
false positives. This study shows different results to other previous reports, showing that the cell 
type, labeling protocol and in vivo paradigm are all likely to affect the reliability of tracking labels. It 
is therefore recommended that labels are thoroughly tested on the specific cell type and in the 
proposed disease model before relying on their validity. In vivo results showed little difference in 
label reliability. However, of those tested, BrdU would be the label of choice due to its reduced 





Chapter 3: Gadolinium-Gold nanoparticles for 
identifying transplanted cells using MRI   . 
3.1 Introduction 
Magnetic Resonance Imaging (MRI) is a powerful tool, with good spatial resolution and no tissue 
depth limitations, affording longitudinal studies in the same population of animals. In the context of 
stroke, MRI is used clinically for diagnosis, to differentiate between haemorrhagic and ischemic 
stroke and to predict prognosis (Ahmed and Masaryk 2004). Preclinically, MRI is used in 
conjunction with behavioural assessment to determine the efficacy of potential therapies in 
rodents and primates (Bihel, Pro-Sistiaga et al. 2010, Boltze, Schmidt et al. 2012). As well as 
reducing the number of experimental groups required for anatomical assessment over a number 
of time points as compared to histology, the number of animals required per group can also be 
reduced due to the increased statistical power of paired observations for a given effect size (Modo 
2009). In order to correlate the location and migration of transplanted cells with anatomical and 
behavioural changes, it is necessary to visualise both the transplanted cells and lesion anatomy 
over time. This presents a challenge due to the spatial resolution of MRI, which, although high 
compared to other in vivo imaging modalities, is relatively low when compared to histology. 
However, recent increases in magnetic field strength allow improved signal to noise ratio in 
shorter imaging times, and advances in contrast agent design are further improving sensitivity. In 
order to visualise transplanted cells, however, a high intracellular concentration of contrast agent 
is required, which is likely to have detrimental effects on cell biology (Brekke, Morgan et al. 2007). 
3.1.1 T1 and T2 Agents 
Most commonly used MRI contrast agents can be split into two categories based on whether they 
predominantly affect the T1 or T2 properties of the labeled material. In terms of stroke, one 
important aspect of assessing potential therapies over time would be to analyse the effects of 
therapies on the anatomy of the lesion, such as volume and topology (Modo, Beech et al. 2009, 
Smith, Stroemer et al. 2011). Both T1w and T2w MR images show the lesion anatomy (Figure 
3.1). However, the T1w image is fairly flat, with the exception of the lesion and ventricles, which 
are hypointense. The T2w image shows improved tissue contrast and anatomical detail, with 




Figure 3.1 T1w and T2w images of a stroke-lesioned rat brain. In the T1w image, the lesion is visible as a 
hypointense area, but there is very little hyperintensity within the brain tissue. The T2w image shows the 
lesion as hyperintense, with additional anatomical detail such as hypointense white matter. 
The most commonly used cell tracking method is currently Superparamagnetic Iron Oxide (SPIO) 
particles (Tang, Sha et al. 2013), which have excellent sensitivity and therefore provide a low cell 
detection threshold. However, their predominant effect is on T2 shortening, producing a 
hypointensity that may be confused with naturally occurring phenomena, such as hematoma and 
white matter, which also produce T2 hypointensity. Gadolinium(III) (Gd3+), however, is 
predominantly a T1 agent, although it does have both T1 and T2 shortening effects. However, the 
advantage is that naturally occurring phenomena are very unlikely to produce a T1 hyperintensity, 
making the signal highly specific to the transplanted cells. A range of Gd based agents are in 
clinical use, for CNS imaging e.g. Gd-DTPA (Magnevist) and Gd-HP-DO3A (ProHance) (Kanal, 
Maravilla et al. 2014). For cell tracking, a high intracellular concentration of agent is required, but 
free Gd3+ ions are highly toxic to cells, making the thermodynamic stability of the chelate of great 
importance to allow uptake of sufficiently high concentrations of agent without compromising cell 
viability (Cabella, Crich et al. 2006). A previous Gd agent design, GRID, showed good cell uptake 
and a useful fluorescence moiety (Brekke, Morgan et al. 2007), but was later shown to impact 
therapeutic efficacy (Modo, Beech et al. 2009). The Meade lab have since worked on improving 
the design of this agent, and we here test the next generation, GdAuNPs. 
3.1.2 GdAuNPs 
GdAuNPs retain the characteristics of bimodality, including a Cy3 moiety, and good cell uptake. 
The macrocyclic chelate HPDO3A is used rather than the linear DTPA used in GRID, which 
reduces the potential for release of free toxic Gd ions. Gold nanoparticle (AuNP) synthesis has 
been developed over the last half century, and optimized methods are now high-yielding and 
reliable. The gold itself is visible by Computed Tomography (Popovtzer, Agrawal et al. 2008) and 
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Electron Microscopy (Horisberger and Rosset 1977), and the large surface area is highly 
functionalizable. Thiols, phosphines and amines have a high affinity for gold, and these can be 
used as anchors to allow further functionalization through, for example, oligonucleotides. 
However, care must be taken, since observed toxicity of AuNPs is normally due to 
functionalization moieties rather than the gold itself (Daniel and Astruc 2004). 
Oligonucleotide-AuNP conjugates (DNA-AuNPs) have found many uses, as oligonucleotide 
loading imparts useful particle characteristics. Higher loading leads firstly to higher particle 
stability, which is thought to be due to the attraction of Na+ to the particle surface, resulting in 
inhibition of DNase enzymes (Seferos, Prigodich et al. 2009). Secondly, high oligonucleotide 
loading leads to improved cellular uptake due to increased protein adsorption onto the surface of 
the nanoparticle, facilitating interaction with the cell membrane (Giljohann, Seferos et al. 2007). 
These properties make it an excellent candidate for cell tracking applications, where high 
intracellular concentration and long-lasting signal are important. The previous version of the 
particle showed improved relaxivity (Song, Xu et al. 2009), and this has since been further 
optimised by Matthew Rotz at Northwestern. The molecular parameters governing water 
exchange (tau m) and rotational correlation time (tau r) have been improved and optimised for 
high field. 
We here aim to test the utility of GdAuNPs for identifying neural stem cells after transplantation 





3.2.1 Particle synthesis 
Particle synthesis was performed by Matthew Rotz at Northwestern. 
All reagents and solvents were purchased from Sigma-Aldrich unless otherwise stated. Citrate 
stabilized AuNPs (15.3±1.4 nm) were synthesized by a previously described protocol (Figure 
3.2). Oligonucleotides were synthesized on solid phase CPGs by standard techniques on a 
MerMade automated synthesizer.  All reagents and protected 3’ Thiol modifier CPGs and C6 
amino modifier dT modified bases were purchased from Glen Research (Sterling, Va). 
Oligonucelotides were deprotected from the solid phase using AMA conditions [(1:1 
methylamine:ammonium hydroxide (sat.)] for one hour. Purification was performed using reverse 
phase high performance liquid chromatography (HPLC) on a Varian HPLC using a mobile phase 
consisting of 30mM triethyl ammonium acetate buffer pH 7 (TEAA) and acetonitrile (ACN).  
Separation was achieved using a gradient of 75% Acetonitrile over 45minutes, as monitored by 
DNA backbone and Cy3 wavelengths at 254 and 546 nm respectively.  Purified oligonucleotides 
were stored at 4 °C until particle synthesis.  Inorganic Gd(III) complex 5 was synthesized using 
standard organic chemistry techniques (vide infra). Characterization was achieved using a Varian 
500 MHz NMR and a Bruker AutoFlex III MALDI spectrometer.   
 





3.2.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS was performed by Matthew Rotz at Northwestern. 
Quantitation of Au and Gd was accomplished using ICP-MS of acid digested samples. 
Specifically, 60 µl of TraceSelect nitric acid (> 69%, Sigma) and 60 µl of TraceSelect HCl (fuming 
37%, Sigma) was added to a 15 mL centrifuge tube.  To this acid is added a 5 µl aliquot of Gd(III) 
DNA AuNPs. Nanopure H2O and multi-element internal standard were added to produce a 
solution of 2% nitric acid (v/v), 2% HCl (v/v) and 5.0ng/ml internal standard up to a total sample 
volume of 3 mL for analysis of Gd(III) content.  Gold samples were prepared in a similar fashion, 
but diluted 10 fold and analysed in a total volume of 10 mL.  Individual Au and Gd(III) elemental 
standards were prepared at 0.500, 1.00, 5.00, 10.0, 25.0, 50.0, 100, and 250ng/ml concentrations 
with 2% nitric acid (v/v), 2% HCl (v/v) and 5.0ng/ml internal standards up to a total sample volume 
of 10ml. ICP-MS was performed on either a computer-controlled (Plasmalab software) Thermo 
(Thermo Fisher Scientific) PQ ExCell ICP-MS equipped with a CETAC 500 autosampler or a 
computer-controlled (Plasmalab software) Thermo X series II ICP-MS equipped with an ESI 
(Omaha) SC-2 autosampler. Each sample was acquired using 1 survey run (10 sweeps) and 3 
main (peak jumping) runs (100 sweeps). The isotopes selected were 197Au, 156,157Gd and 115In, 
165Ho, and 209Bi (as internal standards for data interpolation and machine stability).  Particle 
concentrations were calculated from resultant ICP concentrations of Au by approximating the 
number of gold atoms per particle through the use of particle diameter and the density of atoms in 
bulk gold (here 98,247 Au/AuNP). 
3.2.3 Relaxivity at 1.41T 
Relaxivity measurements were performed by Matthew Rotz at Northwestern 
A concentrated stock of Gd(III)-DNA AuNP conjugates was obtained (700µl).  From this stock, an 
aliquot of 300µl was serially diluted for a total of five solutions.  The five solutions were heated to 
37°C and 250µl of each concentration was placed into a Bruker minispec mq60 NMR 
spectrometer (60 MHz) for measurement of T1 relaxation time. Data was collected using an 
inversion recovery pulse sequence, with a 15s repetition time and 10 data points (average of 4 
measurements per point).  The remaining volumes of each solution were utilized for ICP analysis 
of [Gd(III)]. The inverse of the longitudinal relaxation time (1/T1, s-1) was plotted versus the 
84 
 
Gd(III) concentration (mM). By applying a linear fit to this data, the slope generated is reported as 
the relaxivity of the agent (mM-1 s-1).  Lines were fitted with R2 > 0.99. 
3.2.4 Stability and shelf life analysis 
These experiments were performed by Matthew Rotz at Northwestern 
To assess loss of gadolinium from particles over time, concentrated stock was centrifuged, the 
supernatant decanted and particles resuspended in 0.1x Hank’s Balanced Salt Solution (HBSS) 
at approximately 55nM AuNP per tube and stored either at 4°C or 37°C. ICP-MS was used to 
quantify the initial particle concentrations, including total Gd(III) content per tube. Particles were 
stored for 24 hours, at which time they were vortexed and centrifuged (30 minutes at 4°C, 
21,000g). A sample of the supernatant was removed (containing no AuNPs), which was analysed 
for Gd(III) content. The Gd(III) content measured was normalized to the initial Gd(III) 
concentration of each tube, and quantified as percentage of Gd(III) lost from the particle surface 
into the surrounding solution. This process was repeated in 24 hour increments for a period of two 
weeks. 
In parallel with shelf life stability experiments, a separate aliquot of particles was measured for r1 
and r2 relaxivities the first day after conjugation. Less the particles used for ICP analysis, particles 
were recovered and reconcentrated after the measurement of relaxivity and then placed back into 
storage at 4°C.  This process was repeated on days 8 and 17. 
3.2.5 Cell labeling 
STROC05 human neural stem cells were cultured as in section 2.2.2.1. Particles were diluted to 
the required concentration (0.02, 0.2 2 or 20nM AuNP) in complete growth medium supplemented 
with an additional 2% Human Albumin Solution to improve particle uptake via surface protein 
adsorption (Giljohann, Seferos et al. 2007). This was then added to the cell monolayer, and 
incubated for 24 hours before washing 3x with HBSS and fixing or harvesting.  
3.2.6 In vitro assays 
To assess particle uptake by ICP-MS, cells were seeded in 48 well plates at 150,000 cells/well 
and labeled with different particle concentrations. They were then washed five times with HBSS 
and harvested using Accutase. An accurate cell count was then obtained using a 
haemocytometer and the cell suspension was sent to Northwestern for ICP-MS as in 3.2.2.  
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The Cy3 moiety could be detected using fluorescence microscopy, so images were taken using 
consistent microscopy parameters, and all images were acquired in a single session. These were 
then run through a simple MATLAB code (see Appendix 1) to determine the mean intensity of 
images acquired using this filter set, and the resulting number was divided by the cell number in 
the image (DAPI count) to give relative fluorescence units (RFU) per cell. The RFU per cell of 
unlabeled cells was subtracted to control for background. 
Assays for cell survival, proliferation and differentiation were conducted as in 2.2.4.2 and 2.2.4.3.  
3.2.7 MR Imaging 
MRI sequences were designed and implemented by Wen Ling. All imaging was performed on a 
9.4T Varian system using a volume quadrature coil with inner diameter 38mm (Virtumed). The 






Table 3.1 MR Imaging parameters used for different samples 
   









 T1 map 10.4 40 1 
45x30mm 
T1w 0.5 2.02 1 
T2 map 5 15 to 480 1 




 T1 map 12.2 40 1 
45x25mm T2 map 3 15 to 480 1 





T1 map 10.4 40 1 
30x30mm 
T1w 0.5 2.73 6 
T2 map 4 7.2 to 229 2 





 T1 map 15.4 40 1 
30x30mm T2 map 6 7.2 to 229 2 
T2w 6.1 70.78 8 
 
T1 maps were acquired using global Inversion Recovery (IR) with fast spin echo (FSE) readout 
with Ti values of 0.01, 2, 4, 6, 8, 10 and 10.2s.  
T1w images were acquired using a Gradient Echo Multi Slice (GEMS) sequence, T2w images 
using FSE and T2 maps using Multi Slice Multi Echo (MSME) with 32 echoes, where TE was 
varied between each echo by 15ms in vitro or by 7.2ms in vivo. 
For ex vivo T1 maps using different voxel sizes, the FOV was kept constant at 30x30mm, slice 
thickness 0.5mm. Matrices of 48x48, 64x64, 96x96, 128x128, 192x192 and 256x256 were then 
used to produce voxel volumes of 195, 110, 49, 28, 12 and 7nl. For in vitro cell suspension 
phantoms, an FOV of 45x25mm and slice thickness of 0.5mm were used with matrices of 64x32, 
96x48, 128x64, 192x96, 256x128, 384x192 and 512x256 to give voxel volumes of 4, 8, 17, 31, 
69, 122 and 275nl. 
87 
 
3.2.7.1 In vitro 
For cell pellet phantoms, labeled cells were washed 3 times in HBSS, harvested, counted and 
centrifuged in 0.1ml PCR tubes (Axygen) in PBS. They were then placed into a block of agar gel 
for imaging. 
For cell suspension phantoms, labeled and unlabeled cells were washed 3 times in HBSS, 
harvested, resuspended in PBS and counted. They were then suspended at 10, 50, 100, 150 and 
200 thousand cells/µl in a final concentration of 6% gelatin in PBS, taking into account the cell 
volume as in section 2.2.5.1. The Gd concentration of each phantom was calculated from the 
known cell density and cell uptake of GdAuNP. This could then be plotted against R1 (1/T1) and a 
linear fit applied to give the relaxivity (r1) in mM-1s-1. 
3.2.7.2 In vivo 
Labeled cells were washed 3 times in HBSS, harvested and resuspended in PBS for counting. If 
cell viability was <85%, cells were not taken forward to transplant. Cells were then spun down and 
resuspended at 125,000 cells/µl in 4mg/ml Extracellular Matrix (ECM) hydrogel, kindly provided 
by Stephen Badylak. Stereotactic surgery was performed as described in section 2.2.5.2, using 
the same coordinates, with a total of 5µl of cell suspension injected per site. Labeled cells were 
transplanted into the right hemisphere and unlabeled cells in the left in a total of 5 animals. One 
animal received a total of six cell injections (3 of labeled cells, and 3 unlabeled) at different cell 
densities to give a total of 250,000, 625,000 or 1,000,000 cells per site. The remaining 4 animals 
all received only 2 injections each, of 625,000 labeled and unlabeled cells. 
MRI was performed 24 hours after transplant for all animals. 3 were then sacrificed for ex vivo 
MRI and histology. The remaining 2 were scanned again at 7 days before sacrifice. Animals were 
anesthetized with Isoflurane (4% for induction, 2% for maintenance), and body temperature was 
maintained using a homeothermic water bed controlled via a rectal temperature probe. Breathing 
was monitored using a pressure sensitive “bubble” placed beneath the chest, with a Biopac 
system. 
On sacrifice, perfusion was carried out as in section 2.2.5.3. For ex vivo scans, brains were 
secured in a 50ml falcon tube of PBS. For the animal that received six injections, the brain was 
scanned immediately after perfusion and T1 contrast was consistent with that observed in vivo. 
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For the others, the brains were stored in PBS at 4°C for up to 2 weeks before imaging. There was 
no T1 contrast evident for labeled cells, even when contrast had been apparent on in vivo scans. 
This was attributed to a storage issue, and the results from the ex vivo scans were therefore 
excluded from analysis. 
Histology, Immunohistochemistry and image capture and analysis were conducted as in Chapter 
2. 
3.2.8 Statistics 
Statistical tests were performed using Prism 5.0f (GraphPad). For cell survival and proliferation, 
ANOVAs were used to compare each label concentration with unlabeled controls. For 
differentiation, Mann Whitney tests were used. Pearson correlation was used to correlate SNR 
with voxel size. To generate the contour map showing the in vivo effect of voxel size and cell 
number on T1, Minitab Software was used.  
Values were considered significant where p<0.05. For in vitro assays, three biological replicates, 





3.3.1 Nanoparticle characterization 
GdAuNPs were designed to provide high payload delivery of GdHPDO3A, bearing improved high-
field relaxivity per Gd. Oligonucleotides with a Cy3 moiety were synthesized, and click chemistry 
was used to conjugate these to GdHPDO3A complexes. This DNA was then loaded onto the 
surface of 13nm gold nanoparticles to produce GdAuNPs with ~500 GdHPDO3A per particle 
(Figure 3.3A).  
Prior to the co-incubation of particles with cells, particle relaxivity (R1 and R2) was measured at 
1.41T over a two week period, and was shown to remain consistent (Figure 3.3B). The amount of 
Gd released from the particles into solution was also measured in order to assess the stability of 
the particles and indicate a potential shelf life. When particles were stored at 4°C, no Gd loss was 
observed over two weeks, showing that particles can safely be stored for two weeks between 
production and use. However, when particles were incubated at 37°C, a small but steady loss of 
Gd was observed at a rate of ~0.4% of total Gd per day, resulting in a cumulative loss of <6% of 
total Gd over 2 weeks (Figure 3.3C). This indicates that physiological temperatures negatively 
impact particle stability, but only to a very small degree. However, particle stability in vivo would 




Figure 3.3 GdAuNPs. Particles consist of a gold nanoparticle core loaded with DNA to which the 
GdHPDO3A and Cy3 moieties are attached (A). Particles retain their relaxivity properties (1.41T) over more 
than 2 weeks (B). There is a small amount of Gd(III) loss at 37°C, amounting to <6% of total Gd over 2 
weeks. However, loss is negligible (<0.5%) when particles are stored at 4°C (C). 
 
To test particle performance at high field compared to GdHPDO3A (ProHance), solutions of 
GdAuNPs and GdHPDO3A at the same Gd concentration were imaged at 9.4T, and R1 and R2 
maps were generated (Figure 3.4A). Plotting Gadolinium concentration against R1 gave a molar 
relaxivity (r1) of 6.68mM-1s-1 for GdAuNPs, which was over twice that of GdHPDO3A at 3.07mM-
1s-1(Figure 3.4B), and r2 was 13 times higher for particles (Figure 3.4C). The increase in relaxivity 
seen with GdAuNP compared to ProHance is due to particle design improving molecular 
parameters, such as water exchange (tau m) and rotational correlation time (tau r). 
When relaxivity is expressed per mole of particles, rather than per Gd(III), the comparison to 
GdHPDO3A becomes skewed, here showing a relaxivity of 2548mM-1s-1 (Figure 3.4D), which is 
830 times that of GdHPDO3A (Figure 3.4E). Therefore measurements such as relaxivity should 




Figure 3.4 MRI of GdAuNP compared to ProHance (GdHPDO3A) at 9.4T. R1 and R2 maps were generated 
(A). GdAuNP was shown to have 2.2x the R1 molar relaxivity of GdHPDO3A (B) and 13x the R2 relaxivity. 
Expressing r1 relaxivity on a “per mole of particles” basis suggested that r1 was 830x higher in GdAuNP (D) 
compared to GdHPDO3A (E). 
 
3.3.2 Cell uptake 
The factor having the largest effect on sensitivity of detection is the intracellular Gd concentration 
(Song, Xu et al. 2009). It is therefore important to maximise intracellular Gd concentration without 
impacting cell survival and phenotype. In order to first assess particle uptake into cells, STROC05 
NSCs were incubated for 24 hours with GdAuNPs diluted in growth medium at a range of particle 
concentrations (Figure 3.5A). Cy3 fluorescence could be seen even at the lowest concentration 
of 0.02nM particles (Figure 3.5B), and the particles generally appeared to be colocalized with 
nestin (green, Figure 3.5C), showing a cytoplasmic localization. The amount of Gd per cell was 
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measured by ICP-MS (Figure 3.5D), and Cy3 was measured by relative fluorescence per cell 
(Figure 3.5E), with both showing a similar pattern of uptake across incubation concentrations. 
The uptake appears to be an active process, since the resulting intracellular concentration was 
higher than that of the incubation solution. For example, at 20nM particle concentration, the 
incubation concentration was ~7µM Gadolinium given a loading of 350Gd/particle, whereas the 
final intracellular concentration was 56µM. This is due to the Oligo-DNA coating, which has 
previously been shown to increase particle uptake (Giljohann, Seferos et al. 2007).  
 
Figure 3.5 Cell Uptake of GdAuNPs at different particle incubation concentrations, shown by the fluorescent 
Cy3 moiety (red, A, scale bar = 200µm). Fluorescence was visible even at the lowest concentration (B, scale 
bar = 100µm) and appeared to be localized to the cytoplasm (C). Cell uptake was measured by ICP-MS (D) 
and RFU per cell (E). 
 
3.3.3 Cellular effects in vitro 
GdAuNPs generally seemed to be well tolerated by NSCs. Labeled cells were cultured under 
proliferation conditions overnight, or for seven days in differentiation medium and than stained 
93 
 
with DAPI and Ki67, a marker of cell proliferation (Figure 3.6A). Cell survival was assessed using 
a DAPI count, and was not significantly affected at either day zero or day seven at any particle 
concentration (Figure 3.6B). There appears to be a trend toward decreased survival at day zero 
for the 20nM particle concentration, but this is not statistically significant (p=0.19). Cell 
proliferation was assessed by counting the percentage of total cells expressing Ki67 protein 
(Figure 3.6C). The expected behaviour of down-regulation of Ki67 during a seven day 
differentiation protocol was observed, and this was unaffected by increasing particle 
concentration. At higher concentrations of 50, 100 and 200nM particles (n=1 well per 
concentration), the majority of cells died during the incubation period. It was therefore determined 
that 20nM was the maximum tolerated concentration. In order to assess if this concentration was 
suitable to take forward for imaging experiments, the effect on cell phenotype was assessed. The 
percentage of cells expressing GFAP (as a marker for astrocytic cells), and Tuj (Beta-III-Tubulin, 
for neuronal cell types) was compared between unlabeled cells and those labeled with 20nM 
particles. There was no significant change observed in cell phenotype (Figure 3.6D), showing an 
absence of cell type specific toxicity, or effects on differentiation. 
 
Figure 3.6 Effects of GdAuNPs on neural stem cell biology. Cells at day 0 and day 7 after labeling were 
stained with DAPI and Ki67 (A, scale bar = 200µm). No significant effects were seen on the number of 
surviving cells at any concentration of GdAuNP at day 0 (p=0.19) or day 7 (p=0.63) (B) or on the percentage 
of cells expressing Ki67 at day 0 (p=0.63) or day 7 (p=0.30) (C). Cells were also stained to assess 
phenotypic changes, and no significant differences were seen between those labeled at 20nM particles and 
controls (GFAP, p=0.60; Tuj, p=0.49) (D). 
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3.3.4 Batch variability 
With new particle types, variability between particle batches is a common concern, and 
characterisation of only a single batch can lead to un-representative data that is later found to be 
irreproducible. Here, batches of particles were prepared separately for direct comparison, and 
assessed for consistency of cell uptake and survival effects. The loading of the batches showed 
noticeable variation (Batch 1 = 248Gd/NP; Batch 2 = 345Gd/NP; Batch 3 = 350Gd/NP), and 
therefore the particle concentration (rather than Gd concentration) was standardised across 
experiments. This resulted in a high consistency of Au/cell across batches (Figure 3.7A), 
whereas small differences can be seen in Gd/cell, particularly a lower Gd/cell for Batch 1 
compared to 2 and 3 (Figure 3.7B).  
Cell survival at day 1 was also compared across the three particle batches in order to assess any 
differential toxicity between batches (Figure 3.7C). The three batches performed consistently 
despite the range in incubation concentration of Gd (from 5µM in Batch 1 to 7µM Gd in Batch 3 at 




Figure 3.7 Batch Variability. Three separate batches of GdAuNPs were prepared and used to label cells. 
AuNP uptake was consistent across batches (A), and Gd/cell varied with the Gd-loading of each batch of 
AuNPs (B). Cell survival was also consistent across batches and concentrations (C).  
 
3.3.5 Effect of GdAuNP labeling on MRI of cell pellets 
In order to verify that the level of Gd uptake provided sufficient contrast for MRI detection, labeled 
cells were pelleted and imaged at 9.4T. Cells were labeled either with GdAuNP or with 
GdHPDO3A at the same incubation concentration of Gd, and R1 and R2 maps were generated 
comparing these to blank cells and buffer (Figure 3.8A). Cells labeled with GdHPDO3A showed 
only a minor difference in R1 compared to blank cells, but GdAuNP-labeled cells showed a large 
increase in R1 (Figure 3.8B). This result was attributed to a combination of higher intracellular 
concentrations of Gd and the superior molar relaxivity of the particles compared to ProHance. 
Changes in R2 followed the same pattern (Figure 3.8C), but appeared less dramatic than 
previously seen with solution phantoms. This may due to the low concentration here (56µM), 
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where differences in T1 have been shown to be more marked than differences in T2 (May and 
Pennington 2000). 
 
Figure 3.8 MRI of cell pellets in vitro. Blank cells, and cells labeled either with Gd-HPDO3A or GdAuNP 
were imaged at 9.4T and R1 and R2 maps were generated (A). Cells labeled with GdAuNP showed 
increased relaxivity compared to blank cells and those labeled with Gd-HPDO3A, both R1 (B) and R2 (C). 
 
3.3.6 Effect of cell density and voxel size on MRI detection 
Parameters such as voxel size are often decided based on scanning time and image resolution, 
but voxel size can also affect the efficiency of a contrast agent. To investigate these effects, 
labeled cells were suspended in gelatin at varying cell densities and imaged at 9.4T. At a constant 
field of view (FOV) and slice thickness, the matrix size was varied to give 6 different voxel 
volumes ranging from 4 to 275nl (Figure 3.9A). Signal to noise ratio increased with increasing 
voxel size (Pearson correlation p<0.01), whereas the difference in R1 between labeled and 
unlabeled cells decreased as voxel size increased (p<0.01) Figure 3.9B). This effect could be 
attenuated by selecting an ROI which included only the centre of the sample, excluding the 
coronal area which would be susceptible to partial volume effects with increasing voxel size. 




Relaxivity is affected by the microenvironment of the contrast agent. The r1 molar relaxivity of 
GdAuNPs in cells was calculated as 3.87mM-1s-1 (Figure 3.9D), which is considerably lower than 
their molar relaxivity in solution, which was 6.68mM-1s-1. This is likely due to a combination of 
reduced water access, due to water having to cross the cell membrane to interact with the Gd 
complex, and the presence of intracellular proteins. Their interaction with the Gd complex can 
affect the tumbling frequency of Gd, thereby reducing its relaxivity.  
 
Figure 3.9 Labeled and unlabeled cells were suspended in gelatin at different cell densities (A, + = labeled 
cells, - = blank cells). Increasing voxel size had higher SNR but less contrast between labeled and 
unlabeled cells (B). The decrease in contrast could be attenuated by selecting ROIs in the centre of the 




3.3.7 Cell detection in vivo 
To assess cell visibility on MRI in vivo, labeled and unlabeled cells were transplanted into healthy 
rat striatum and MR images were taken the following day. Labeled cells were clearly visible on 
T1w images (Figure 3.10A, right hemisphere), whereas unlabeled cells showed no change in 
contrast (left hemisphere). T2w images showed only some oedema and tissue damage, with 
neither labeled nor unlabeled cells visible. This was supported by histology, where transplanted 
cells in the right hemisphere showed red fluorescence consistent with the Cy3 moiety of 
GdAuNPs, whereas this was absent from unlabeled cells in the left hemisphere. Both populations 
were visible using human nuclear antigen (HNA). 
At higher magnification, both Cy3 fluorescence and dark spots consistent with gold were 
observed within the graft (Figure 3.10B). GdAuNP were well colocalized with HNA staining, with 
71% of cells being positive for both HNA and GdAuNP (Figure 3.10C). False negatives (HNA+, 
GdAuNP-) were more numerous than false positives (HNA-, GdAuNP+) at 29% compared to 
<0.5%. This suggests that the MR contrast in vivo is more likely to be an underestimation of 




Figure 3.10 Transplanted GdAuNP labeled cells are clearly visible on T1w MR images, whereas unlabeled 
cells in the left hemisphere are not. Neither are visible on T2w images. Histology shows GdAuNP (red) and 
HNA labeling all transplanted cells (green, A). A higher magnification image shows good colocalisation of 





3.3.8 Serial imaging of transplanted cells over one week 
One of the benefits of MRI is the ability to image over time in the same animals in order to track 
anatomical changes and assess their correlation with the behaviour of transplanted cells. 
However, contrast agents often remain visible after cell death, generating false positive detection 
(Berman, Galpoththawela et al. 2011). In order to assess whether GdAuNP continue to generate 
T1 hyperintensity after cell death, labeled and unlabeled human cells were transplanted into the 
rat brain without immune suppression and allowed to die over 7 days. MR images were obtained 
after 24 hours while cells remained viable, and again at day 7 when very few transplanted cells 
were detected by histology. Both animals showed the expected hyperintensity on T1w images at 
day 1, but this contrast had largely disappeared by day 7 (Figure 3.11). When this was compared 
with histology, very little staining was seen either for GdAuNPs or HNA, which is indicative of very 
low cell survival. This shows that upon the death of transplanted cells, the remaining agent is not 
detected in the extracellular space or within host cells. This is likely due to the presence of high 
levels of DNases such as CAD (Caspase Activated Deoxyribonuclease) during apoptosis, which 
may break down the oligonucleotide component of GdAuNPs, thereby leaving GdHPDO3A in 




Figure 3.11 Seven days after transplantation, very little contrast is seen on the MR images, corrsponding 
with a lack of histological staining for transplanted cells (HNA) or GdAuNP. 
 
3.3.9 Effect of cell number and voxel size on cell detection 
In order to assess the effect of voxel size and cell number on detection by MRI, one animal 
received injections containing three different cell numbers, both labeled and unlabeled. The 
animal was sacrificed and perfused with PFA the following day and the brain was immediately 
imaged in PBS at 9.4T. Retaining a constant FOV (30x30mm) and slice thickness (0.5mm), the 
matrix size was varied to acquire T1 maps with voxel volumes ranging from 7 to 195nl. At the 
smallest voxel volume, the T1 shortening can be clearly seen for all GdAuNP labeled transplants, 
but this is less clear at 49nl and no longer visible at 195nl (Figure 3.12A). 
In order to quantify this effect, the T1 of an ROI within the area occupied by labeled cells was 
compared to an area occupied by unlabeled cells for each map. The resulting contour map shows 
102 
 
that voxel size has a much larger effect on the observed change in T1 than total cell number 
(Figure 3.12B). This is likely due to inhomogeneity of the sample, as the probability of including 
unlabeled host cells in any given voxel increases with voxel size, thereby effectively reducing the 
agent concentration. This shows that the frequently used description of a detection threshold as a 
number of “cells per voxel” can potentially be misleading as this will vary considerably depending 





Figure 3.12 T1 maps of 3 different injection sites were acquired at 6 different voxel sizes (A). The  change in 
T1 of labeled compared to unlabeled cells was compared across cell number and voxel volume, with voxel 





In this work we have shown the potential of a novel Gd nanoparticle, GdAuNP, for tracking neural 
stem cells in vivo. Our work indicates that the particles are easily taken up into cells, show 
consistent characteristics between batches, and have no significant effects on the biology of 
human neural stem cells at the concentrations used. Labeled cells can be detected in vivo using 
T1w images, and contrast is no longer seen after cell death. The effect of voxel size on cell 
detection was also investigated, and partial volume effects were found to play a significant role. 
This agent shows promise for cell tracking, but requires further investigation as to its efficacy 
during long term cell survival. 
3.4.1 Challenges in T1 agent detection 
A major challenge in cell detection using T1 agents is to achieve an optimal intracellular 
concentration and distribution of agent for cellular imaging. Since the sensitivity of T1 based MR 
probes is inherently lower than T2 agents (Helm 2010), a high concentration is required for 
detection. However, dosing of cells with high concentrations of contrast agents can increase the 
risk of negative effects on both labeled cells and surrounding tissue (Modo, Beech et al. 2009).  In 
addition, Gd(III) agent stability can be improved by the use of macrocyclic, rather than linear 
chelates due to improved kinetic stability (Idee, Port et al. 2009), and as such, these are being 
used increasingly in the design of new particles for cell tracking and may attenuate cellular 
effects.  
As the intracellular concentration increases, the localisation of the agent within the cell becomes 
increasingly important. Nonspecific endocytosis or pinocytosis is the most commonly used route 
of agent uptake due to its simplicity and efficiency, but this results in localisation of the agent to 
endosomes, which has been shown to produce a quenching of the T1 effect above 1010 Gd/cell 
(Terreno, Geninatti Crich et al. 2006). It has further been shown that there is no such quenching 
of the T2 effect at high agent concentrations, and that the observed T2 relaxivity in lysosome 
localised agent may instead be increased, potentially due to susceptibility effects (Kok, Hak et al. 
2009). The concentration of agent seen in the present study was 108 Gd/cell, below the threshold 
for quenching and subsequently produced clear signal change on T1w images. However, no 
signal change was visible on T2w images in vivo, suggesting that the concentration threshold for 
a T2 effect is higher than that for T1, potentially due to increased “noise” as brain tissue itself has 
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a lot of T2 contrast. In previous studies using GRID (Gadolinium Rhodamine Dextran), a 
concentration of 9 x 1010 Gd/cell was achieved, and labeled cells were visible on T2w but not T1w 
images, supporting this hypothesis (Brekke, Morgan et al. 2007, Modo, Beech et al. 2009). 
The interplay between an agent’s properties, its microenvironment and the imaging parameters 
used result in a seemingly elusive “sweet spot” for optimum contrast. Molecular parameters 
interact with magnetic field strength, resulting in a fairly narrow range of optimal water exchange 
and tumbling frequency for a given field (Caravan, Farrar et al. 2009). However, these molecular 
parameters are highly sensitive to events such as protein binding and water access, resulting in 
the differential relaxivity between agents in solution and inside cells as seen here and elsewhere 
(Kok, Hak et al. 2009). Partial volume effects are much discussed in the context of diffusion 
weighted MRI (Roine, Jeurissen et al. 2014), but little attention has been given to them in the 
context of cell tracking. To assess efficacy of potential cell transplant therapies and correlate cell 
presence and migration with clinically relevant outcomes such as motor coordination, e.g. as 
assessed by the footfault test (Modo, Stroemer et al. 2000), large animal numbers are required 
per study. This necessitates shorter imaging times per animal in order to increase throughput, and 
lower resolution images are significantly faster to acquire and have a better SNR. However we 
show here that the use of large voxels is likely to result in a significant underestimation of cell 
number. The selection of voxel size must therefore be based on a balance between acceptable 
cell detection thresholds, SNR and imaging time constraints. At high field, SNR is not such a 
significant concern as at lower field, so smaller voxel volumes will give the most accurate cell 
detection. 
3.4.2 Specificity of cell detection 
Since there is normally very little contrast in a T1w image of the brain, T1 contrast agents are able 
to generate a very specific signal that is less likely to be confused with naturally occurring 
phenomena than a T2 based agent. However the question of agent specificity to the cells remains 
an issue. Any agent present outside transplanted cells, whether from the injectate solution or after 
leakage from labeled cells, will be detected as contrast. Bimodal agents allow validation of MRI 
contrast using histology, as shown here and elsewhere (Detante, Valable et al. 2012), in order to 
assess the specificity of cell detection. One area of particular concern is the fate of the label after 
cell death, as lingering label could produce erroneous contrast. The data shown here show an 
absence of MRI contrast after cell death, consistent with the findings of Guenoun, Ruggiero et al. 
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(2013), who showed that Gd contrast was quickly reduced below the detection threshold on 
transplantation of dead labeled cells, compared to SPIO-labeled cells, where contrast persisted 
for over 2 weeks in the absence of viable cells. 
For this reason, it can be expected that Gd(III) based agents should not produce a significant 
number of false positives, but false negatives may be more of a problem. T1 agents have a 
generally lower sensitivity, and loss of contrast can be seen as a result of intracellular localisation, 
or sub-optimal agent concentration or protein interaction. Additionally, data here shows that 29% 
of transplanted cells did not appear to contain agent. It is therefore important to thoroughly assess 
all these factors before relying on Gd labeling as a sole indicator of cell location. 
3.4.3 Utility of cellular MRI in transplantation studies 
Cellular MRI has proven to be an extremely useful source of information in transplantation 
studies, showing, for example, the time course of cell migration from the contralateral hemisphere 
to the ischemic area (Hoehn, Kustermann et al. 2002). Many groups saw similar cell behaviour 
after transplant into stroke models, corroborating its utility (Adamczak and Hoehn 2012). 
However, much remains to be elucidated regarding the therapeutic mechanism of transplanted 
cells and their potential for tissue replacement rather than purely neurotrophic effects. In this 
context, the combination of cell tracking with other MRI techniques to assess angiogenesis and 
de novo tissue formation may be a powerful combination. In particular, the use of diffusion tensor 
imaging to show restoration of connectivity across a lesioned area may be highly pertinent. 
However, the issue of potential label toxicity remains. New agents are subjected to an increasing 
battery of in vitro tests, which provide valuable data. But this may not be sufficient to assess the in 
vivo ramifications of potentially compromised cells, or label effects on local tissue. Indeed, even 
after proving useful for cell tracking in vivo in the disease model (Modo, Mellodew et al. 2004) and 
using in vitro testing to select non-toxic labeling conditions (Brekke, Morgan et al. 2007), GRID 
was still shown to affect the therapeutic efficacy of transplanted cells (Modo, Beech et al. 2009). It 
is therefore paramount that any investigation into therapeutic efficacy of cell transplant that 
utilises cell tracking includes an unlabeled cell control for therapeutic outcome measures. 
Eventually, utilising cell tracking in clinical trials would provide a wealth of data in terms of the 
exact location of cell delivery, cell migration, and interaction with the lesion which could be 
correlated with patient outcome to better inform experimental design for the next phase. However 
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there are several considerations. Firstly, since the majority of cell tracking applications do not 
provide additional therapeutic properties, their use must be carefully considered in terms of a risk-
benefit analysis to the patients (Modo, Kolosnjaj-Tabi et al. 2013). Secondly, although many 
agents are approved for clinical use, the dose recommendations are based on dilution in a large 
volume of blood, and may need to be reconsidered in terms of maximal local concentration. And 
finally, agent characteristics must be optimised for clinical field strength and imaging parameters, 
which often differ substantially from those used experimentally.  
 
3.5 Conclusions 
GdAuNPs in this system appear to have several advantages for cell tracking in the brain. 
Specifically, they provide clear contrast on T1w images, while leaving T2w images unchanged to 
allow anatomical assessment. Additionally, the agent does not continue to show MR contrast after 
cell death or label host cells, thereby showing a low likelihood of false positive contrast. Although 
further in vivo testing is required to establish their long term tracking potential, GdAuNPs are a 





Chapter 4: The potential of ParaCEST for 
tracking multiple cell populations in vivo 
4.1 Introduction 
Current cell transplantation paradigms in clinical trials are based on the use of a single cell type, 
with the therapeutic mechanism thought to based more on beneficial effects on host tissue than 
active integration of the transplant. Improved behavioural outcomes after stroke have been 
observed after implantation of human neural stem cells even with a very limited amount of 
neuronal differentiation. However, although these treatments reduce symptoms, they do not result 
in a full recovery, and large lesions do not completely disappear, although reduction in their size 
has been observed (Smith, Stroemer et al. 2011). Therefore, a potential avenue of improved 
treatment would be to place neural stem cells directly into the lesion cavity with structural support 
in the form of biomaterials. This approach has already been shown to produce a primitive de novo 
tissue (Park, Teng et al. 2002, Bible, Chau et al. 2009). However, in order for the graft to survive 
long term, vascularisation is crucial (Bible, Qutachi et al. 2012). In islet grafts, adding endothelial 
cells to the graft has been shown to improve vascularization and functional outcome (Oh, Oh et 
al. 2013). There is therefore reason to believe that this approach may also be helpful in the 
context of tissue engineering in the CNS, such as ischemic stroke and TBI (Zhang, Zhang et al. 
2013).  
The requirement for multicomponent non-invasive monitoring is one that cannot be met by current 
techniques. Simultaneous use of T1 and T2 contrast agents has been suggested as a potential 
mechanism, and shown to be able to detect two cell populations within a biomaterial (Di Corato, 
Gazeau et al. 2013). However, this method potentially causes confusion with anatomical imaging, 
and has so far not been demonstrated with cells occupying the same voxel, as the effects of the 
two agents are likely to interact. Another option would be to use the same contrast agent to label 
both cell types. However, this would only allow tracking of the graft as a whole, rather than 
allowing independent imaging of separate populations. 
Chemical exchange saturation transfer (CEST) offers several advantages over currently used 
methodology. Firstly, the contrast can be turned “on” and “off” due to the requirement for a 
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presaturation radiofrequency (RF) pulse to visualise the CEST target. Secondly, a number of 
CEST agents can potentially be combined if their chemical shifts are far enough apart, allowing 
selective visualisation of one target at a time. The basis of CEST is that the protons associated 
with the molecule of interest are in exchange with the bulk water, and these have distinct 
chemical shifts (Figure 4.1A). When an RF pulse at their specific resonance frequency is applied, 
only the protons of interest will flip and are then exchanged with the bulk water. This results in a 
decreased bulk water signal (Figure 4.1B). This is normally displayed as a z spectrum. Water is 
assigned a reference value of 0ppm, and the intensity of the water signal is plotted at each 
chemical shift after normalisation to a reference frequency without CEST effects (e.g. -300ppm). 
Thus any reduction in the bulk water signal caused by CEST results in a dip (Figure 4.1C, black 
line). Subtracting the intensity values at opposite sides of the water peak (e.g. Intensity at -18ppm 
– Intensity at +18ppm) gives an asymmetry value, which is the most common way of expressing 
CEST contrast (Figure 4.1C, grey line).  
 
Figure 4.1 Schematic of CEST experiment. (a) Pool A (solvent) is in exchange 
with pool B (solute). (b) Pools A and B have distinct chemical shifts, with the 
difference of ΔCS. RF is applied on-resonance with pool B resulting in saturation 
transfer and signal decrease of pool A. (c) z-spectrum: normalized water intensity 
(I/I0) vs. off-resonance frequency of the saturating RF (ΔRF). Water resonance is 
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assigned 0ppm value. MTRasym: z-spectrum asymmetry vs. RF off-resonance 
value. Vinogradov, Sherry et al. (2013) 
CEST is so far most commonly used to detect endogenous molecules, such as glucose (Zu, 
Spear et al. 2014) or glycosaminoglycans (Saar, Zhang et al. 2012), which have relatively small 
chemical shifts, normally in the region of 1-5ppm. Paramagnetic CEST (paraCEST) refers to the 
use of paramagnetic compounds as the solute providing the chemical exchange with bulk water 
(Woods, Woessner et al. 2006). This allows a larger chemical shift than is found in endogenous 
molecules, allowing reduced noise. Lanthanide complexes are the most commonly used and have 
been used for applications such as pH and temperature mapping (McVicar, Li et al. 2013). Their 
potential for cell tracking was first investigated in vitro using Eu(dotamGly) and Tb(dotamGly), but 
was hampered by low biocompatibility and high power requirements (Aime, Carrera et al. 2005). 
Modified agents were then generated utilising the biocompatible HPDO3A chelate used in the 
clinical Gd agent ProHance. It was shown that these could be used to visualise two cell 
populations in vivo using MR spectrometry (Ferrauto, Castelli et al. 2012). 
ParaCEST therefore provides the potential to label two cell populations and detect each one 
selectively and independently, whilst preserving anatomical imaging. Here we aim to test this 
potential in the context of tissue engineering for stroke. STROC05 human fetal neural stem cells 
(NSCs) have been shown to differentiate into the different neural and glial cells of the CNS (El 
Akabawy, Martinez-Medina et al. 2011), and to form a primitive neural tissue inside the lesion 
cavity (Bible, Dell'acqua et al. 2012). By implanting these cells with human cerebral microvascular 
endothelial cells, it may be possible to vascularise the graft and allow long-term survival. Here we 
assess uptake of two paraCEST agents, Eu-HPDO3A and Yb-HPDO3A, into the two cell types in 
order to assess whether the two agents can be selectively detected in vitro and in vivo after 






4.2.1 Agent Synthesis 
Agent Synthesis was performed by Giuseppe Ferrauto at University of Turin, Italy 
HPDO3A ligand was kindly provided by Bracco Imaging S.p.A. (Colleretto Giacosa (TO), Italy). 
Yb2O3 and Eu2O3 were purchased from Sigma-Aldrich. The synthesis of Yb(III)- and Eu(III)-
complexes was carried out mixing the lanthanide oxide Ln2O3 and the ligand HPDO3A (1:2 molar 
ratio) in water. The mixture has been let to react for 2 weeks under stirring and heating at 80°C. 
The purity of the compounds was around 90% as evaluated by measuring the bulk magnetic 
susceptibility (BMS) shifts of 1H NMR resonance signals of solution (tert-butanol in water) 
containing the compound with the respect to the same solution without paramagnetic compound 
(Evans’ Method) (Corsi, Platas-Iglesias et al. 2001). 
4.2.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS was performed by Giuseppe Ferrauto at University of Turin, Italy 
The Lanthanide content of cells was determined using inductively coupled plasma mass 
spectrometry (ICP-MS). Cells were collected in 0.1ml of PBS and destroyed by sonication. Then 
they were digested with concentrated HNO3 (70%) under microwave heating (Milestone 
MicroSYNTH Microwave labstation equipped with an optical fibre temperature control and HPR-
1000/6M six position high-pressure reactor, Bergamo, Italy). After the mineralization, each sample 
was taken with 2 mL of ultrapure water and analysed by ICP-MS by using a Thermo Scientific 
ELEMENT 2 ICP-MS -Finnigan, Rodano (MI). Three replicates of each sample solution were 
analysed. The concentration of protein was determined by the Bradford method using bovine 
serum albumin as standard. 
4.2.3 Cell labeling 
To assess the effect of different labeling methods and parameters on cell uptake and survival, 
labeled cells were labeled by electroporation or pinocytosis and assessed for agent presence, 




4.2.3.1 Optimisation of Electroporation  
The Eppendorf Multiporator was used for all electroporation experiments, and a theoretical set of 
conditions was calculated from the Eppendorf user guide, based on cell size (530V, 100µs, 3x106 
cells/ml) (Eppendorf 2006). Agents were dissolved in Hypoosmolar or Isoosmolar electroporation 
buffer (90mOsm and 280mOsm respectively, Eppendorf). In order to estimate the best 
parameters to test for each cell type, Since the paraCEST agents are not fluorescent, a proxy 
agent, Carboxyfluorescein (Sigma), was used to define ranges of conditions to test, since uptake 
could be assessed quickly within the lab, whereas samples containing paraCEST agents had to 
be sent to Turin for analysis. Using carboxyfluorescein, the effect of varying electroporation 
parameters on agent uptake and cell survival was assessed in each cell type. Voltages, pulse 
lengths, cell densities, agent concentration and buffer osmolarity were varied around the initial 
estimates to cover a broad range and identify ranges showing potential for maximising agent 
uptake, whilst minimising effects on cell survival. Concentrations of carboxyfluorescein were 
selected based on Di Gregorio, Ferrauto et al. (2013) and the agent’s solubility in electroporation 
buffer, as the maximum concentration achievable was 5mM. The exact parameters used are 
shown in  
. The controls for cell survival and to correct for background auto-fluorescence were cells that had 
not undergone electroporation. 
Table 4.1 Electroporation conditions for carboxyfluorescein condition testing 
Figure Voltage  
(V) 
Pulse length  
(µs) 
Cell density  
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After electroporation, cells were plated onto coverslips and incubated overnight before fixing with 
PFA as in section 2.2.2.4 and mounting in Vectashield + DAPI. Fluorescence images were then 
taken as previously described (section 2.2.7) using consistent imaging parameters and obtaining 
all images in the same session in a randomised fashion to minimise variation. The number of 
DAPI cells was then counted as in section 2.2.4.2 to give a measure of cell survival, and the 
relative intensity in the green channel was measured using MATLAB (See Appendix 1). The 
intensity of each image was then divided by the number of cells to give Relative Fluorescence 
Units (RFU) per cell, which was used as an estimation of agent uptake. The results of this 
experiment are shown in Figure 4.2, and were used to inform the selection of parameters to test 
with the paraCEST agents.  
Decreasing the voltage did not significantly affect cell survival for either cell type, but agent uptake 
was increased in both. Increasing the voltage had a dramatic effect on agent uptake for NSCs, 
but not ECs (Figure 4.2A). Increased voltage was therefore selected as a parameter to take 
forward for assessment for NSCs with paraCEST agent. However, since cell survival was also 
affected, the range was restricted to 530-750V to avoid the most extreme effects. 
Decreasing the pulse length improved cell survival for NSCs, but uptake was also affected. 
Increasing pulse length severely affected NSC survival with only a moderate increase in uptake. 
However, for ECs there was an increase in uptake without a significant effect on survival (Figure 
4.2B). Increased pulse length was therefore selected as a parameter to test for ECs with the 
paraCEST agent. Since survival was not significantly affected, the range of pulse lengths tested 
was extended to 100-500µs in order to maximise uptake effects.  
Cell density did not appear to be a major factor with carboxyfluorescein, although lower cell 
density slightly decreased cell survival for both cell types (Figure 4.2C). However, a pilot imaging 
experiment with NSCs labeled with Eu (200mM, 530V, 100µs) showed similar CEST contrast and 
survival when electroporated at 3 or 9 x 106 cells/ml (Figure 4.2F). Cell densities of 3, 6 and 9 x 
106 cells/ml were therefore also taken forward for further testing. 
Increasing agent concentration increased agent uptake for both cell types, and affected cell 
survival (Figure 4.2D). However, direct parallels cannot be drawn with the paraCEST agents 
since the concentration range is so different. Ferrauto, Castelli et al. (2012) previously used 
100mM of each agent for labeling via pinocytosis. For this reason, the paraCEST agents also 
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have large effects on the osmolarity of the electroporation solution, which has additional effects 
on cell survival and uptake (Figure 4.2E). Therefore the agent concentration was maximised 
within the limitation of maintaining isoosmolar conditions and kept constant at 200mM to give a 




Figure 4.2 Preliminary assessment of electroporation parameters. Varying the voltage of 
the electroporation pulse (A) showed little effect of agent uptake in ECs (D3 cells, orange 
bars), but a dramatic increase in uptake for NSCs (STROC05, red bars), but also a 
decrease in survival. Increasing the length of the pulse (B) showed an increase in agent 
uptake into ECs, with no significant effect on cell survival, but for NSCs showed a small 
increase in agent uptake with a large drop in cell survival. Increasing the cell density 
during electroporation (C) appeared to have little effect on agent uptake, but increased cell 
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survival for both cell types. Increasing agent concentration (D) showed an increase in 
agent uptake for both cell types, but also a decrease in cell survival. 
 
The conditions therefore taken forward to test with paraCEST agents were: 
• Constant agent concentration of 200mM 
• Cell densities of 3, 6 and 9 x 106 cells/ml for both cell types 
• Voltages of 530, 650 and 750V for NSCs. Constant at 530V for ECs 
• Pulse lengths of 100, 300 and 500µs for ECs. Constant at 100µs for NSCs. 
4.2.3.2 Pinocytosis 
To allow agent uptake via pinocytosis, the agent was dissolved in the cells’ normal growth 
medium at the required concentration (50, 100 or 200mM) and pre-warmed to 37°C. A well of 
cells at around 60% confluence for NSCs or 80% confluence for ECs cells was selected, and the 
media aspirated and replaced with growth media containing dissolved agent. They were then 
incubated at 37°C, 5% CO2 for the required incubation time of 12, 24 or 48 hours. N=3 per 
condition. 
Assessment of cell survival, and sample collection for ICP-MS: For electroporation, cells were 
electroporated with agent and then placed into a 48 well plate at 150,000 cells/well and incubated 
overnight. For pinocytosis, cells were plated into 48 well plates at 150,000cells/well and allowed 
to attach overnight. The medium was then changed to include ParaCEST agent, and cells were 
incubated for the appropriate time. Unlabeled cells were grown alongside to control for the effect 
of time on cell number. 
Monolayers were then rinsed three times with HBSS before being harvested with Accutase. A cell 
count was obtained using a haemocytometer (average of 3 counts) and a known volume of 
suspension was then analysed by ICP-MS. In order to calculate intracellular concentration, the 
total lanthanide content in moles was divided by the number of cells present in the suspension to 
provide moles/cell. This was then divided by the average volume of a cell (3.91pl) to provide the 
Molar concentration. 
The results of this experiment are shown in Figure 4.7, and final conditions were then selected to 
take forward.  
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4.2.4   Cell preparation for imaging 
Cells were harvested, resuspended in PBS and counted. They were then resuspended at 3 x 106 
cells/ml in hypoosmolar electroporation buffer (Eppendorf) containing agent dissolved at 200mM. 
400µl of suspension was then transferred to a 2mm electroporation cuvette, and 1 pulse was 
applied at 530V for 100µs. The mixture was then left in the cuvette for 15min at room temperature 
to allow diffusion of agent. The mixture was then carefully transferred to a coated flask containing 
pre-warmed proliferation medium with a dilution ratio of at least 1:10. Cells were incubated 
overnight before washing three times with HBSS and harvesting for in vitro imaging or cell 
transplantation. 
Cells were prepared for phantoms as in section 3.2.7.1. Due to the CEST effects of gelatin, all MR 
imaging was performed on cell pellets in PBS. Where dilution of labeled cells was required to 
produce a particular ratio of labeled cells, unlabeled cells were used to occupy the required 
volume, rather than suspending in gel. Since the agent detection characteristics are affected by 
their incorporation into cells, cell viability during imaging acquisition is important. Therefore, the 
available scanning time for samples was determined by measuring cell viability by trypan blue 
exclusion after different scanning times, compared to pre-scan viability and an un-scanned control 
left at room temperature (Figure 4.3). There was no significant difference compared to pre-scan 
viability at 1.5, 3 or 5 hours, but after 7 hours viability was significantly reduced (61%, p<0.0001 
by 2 way ANOVA). Scanning time for in vitro samples was therefore restricted to 5 hours or less. 
 
Figure 4.3 Cell viability during ParaCEST MRI. Cell viability remained consistent over 5 




4.2.5 MR Imaging  
MRI sequences were designed and implemented by Wen Ling at University of Pittsburgh. 
MR Images were acquired on a 9.4T horizontal bore Varian magnet equipped with Agilent VnmrJ 
3.1 console. A volumetric birdcage quadrature coil was designed by Mike Modo and Wen Ling, 
and built by Virtumed LLC. It has a diameter of 30mm and effective length in the z direction of 
25mm and can handle Radiofrequency (RF) power of up to 55µT/ 5sec input on a 250~300g rat.  
The implementation of paraCEST imaging applications poses a number of challenges in terms of 
MRI: 
B0 homogeneity: The fidelity of CEST contrast is very much dependent on B0 homogeneity, 
which refers to  the field generated by the main magnet. Modern animal MRI scanners may have 
inherent variability ∆B0 ~100Hz (0.2ppm at 9.4T). This variation, plus tissue inhomogeneity, may 
cause CEST contrast error ~±0.5% for Eu agent. Given that the CEST contrast observed between 
labeled and unlabeled cells is ~1.0-1.5%, an error of 0.5% cannot be tolerated. To address this 
issue, an accurate Water Saturation Shift Referencing (WASSR) B0 field map was generated for 
each CEST scan. A typical rapid acquisition relaxation enhancement (RARE) spin–echo 
sequence was used (RARE factor of 32), with an echo time (TE) of 3.8 ms, and a relaxation time 
(TR) of 3s. The presaturation pulse is 1ms at 0.1µT, and the offset region is set between ±0.3ppm 
with 0.04ppm per step. The resultant data allowed generation of a z-spectrum for each voxel 
using spline-fitting. In order to obtain accurate water frequency for each voxel, a maximum 
symmetry algorithm was applied (Stancanello, Terreno et al. 2008). The resulting map was 
incorporated into the z-spectra calculation for CEST contrast on voxel-by-voxel basis. 
B1 homogeneity: A high quality CEST image also requires high B1 homogeneity. This was 
addressed in the coil design, by using volumetric birdcage quadrature coil with two RF channels, 
0º and 90º RF input phase simultaneously. This resulted in low B1 variation across the rat brain. 
High Power requirement: Both paraCEST agents require RF input power >20µT (for Yb, ~56µT) 
with a pulse duration of 800ms-1200ms (100% duty cycle within this period). This is beyond the 
capacity of the average coil, but was addressed here by using high quality, high power capacitors 
in the building of the coil. The high power also has the potential to damage the magnet itself. The 
Varian system used here has a maximum input of 1kW, and all safety features to protect the 
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hardware have been removed. In order to avoid a high level of reflected power that could damage 
the hardware, but still fully utilise the input power, decoupling between the two RF channels in the 
quadrature coil was ~-40dB to allow effective coil loading for a 300g rat. Optimal tuning and 
matching after loading the sample is also of the utmost importance here. Even after taking the 
above measures, the high power increased the specific absorption rate (SAR), thereby generating 
heat in the sample. The SAR generated by a given sequence is proportional to B12. A T2 weighted 
image can be generated by a RARE sequence where RF power ~10µT, 5% duty cycle (the 
percentage of the TR that the RF pulse is on), with a TR of 3s. To generate CEST contrast, an 
additional 1000ms pulse of 56µT was appended at the beginning of the sequence. This results in 
an RF power of 56µT with a 38% duty cycle. The SAR would therefore be 238 times [(56/10)2 X 
(38/5) = 238] higher with the CEST pulse than the standard RARE protocol. This was a significant 
concern regarding animal safety. However, the use of a long TR, particularly for Yb (10s), allowed 
time for excess energy to dissipate between each excitation, so that the final protocol did not 
induce any excessive increase in animal temperature. This was measured at 37°C ± 1°C as 
measured by rectal probe (Figure 4.4), which is in line with FDA guidelines of maximum 1°C 
whole body heating due to SAR effects (Zaremba 2002). However, this resulted in a lengthy 
acquisition time. 
 




Final MR Imaging Protocol: 
T2w images were acquired as in section 3.2.7 
For acquisition of z spectra, a frequency offset range of ±110ppm was investigated, with an 
additional reference offset at ±300ppm. A typical RARE spin–echo sequence was used (RARE 
factor of 8 or 16 depending on the T2 of the sample), with an echo time (TE) of 4.2 or 8.4ms, and 
a relaxation time (TR) of 3s for Eu and 8s for Yb. An isotropic 64×64 acquisition matrix with a FOV 
of 30x30mm and a slice thickness of 1mm were used. The whole sequence was preceded by a 
saturation scheme consisting of a continuous rectangular wave pulse. For EuHPDO3A, the 
presaturation pulse was 800ms long, with a RF B1 intensity of 23µT. For YbHPDO3A, the 
presaturation pulse was 600ms, with a RF B1 intensity of 56µT.  
For in vivo experiments, the scanning time had to be kept within reasonable limits, so full z 
spectra were not acquired. Instead, a number of points were acquired around the specific 
chemical shift of the agent, along with reference points of 0 and -300ppm. For Eu, the offsets 
chosen were ±13.5ppm, ±16ppm, ±17ppm, ±18ppm, ±19ppm and ±20ppm. Yb has two exchange 
sites, one at 69ppm, and one at 97ppm. When targeting 69ppm, offsets selected were ±60ppm, 
±67ppm, ±68ppm, ±69ppm, ±70ppm and ±71ppm. When targeting 97ppm, offsets were ±90ppm, 
±95ppm, ±96ppm, ±97ppm, ±98ppm and ±100ppm. 
The z-spectra were interpolated by smoothing splines to identify the zero-offset on a voxel-by-
voxel basis of the bulk water and, then, to assess the correct ST% value over the entire range of 
frequency offsets investigated. Custom-made software, compiled in the MATLAB platform 
(MathWorks), was used (Raya, Dietrich et al. 2010). The extent of CEST effect is calculated as 
follows: 
ST% = (1 – (MS/M0)) x 100 
where MS is the intensity of the bulk water NMR signal after the irradiation on resonance (Δω) of 





4.2.6 Magnetisation transfer (MT) simulation 
In the current in vivo application of paraCEST, due to its extremely lengthy acquisition, it is not 
possible to experimentally obtain full z-spectra. However, the exchange between free bulk water 
pool and proton pool associated with Eu/Yb can be readily described by the Bloch-McConnell 
equation. Chemical/physical properties of both agents, and the tissue properties of the rat brain 
are either published or were obtained from in vitro experiments at the beginning of the project. As 
a result, numerically solving this equation to obtain full z-spectra will help us address some of the 
potential problems. 
In MR theory, a homogenously mixed proton population with the same MR properties (T1,T2, 
exchange rate with other proton population, temperature, etc.) can be categorised as one pool. In 
our system, Eu associated protons and Yb associated protons are the two pools of interest. When 
in solution, the CEST effect is described purely by the exchange of these pools with the bulk free 
water. However, in the presence of cells or tissue, there is an additional pool of protons, which are 
those bound to biological molecules, such as those within cell membranes and extracellular 
matrix. The properties of this pool are quite different from the those of the free water pool. It has a 
very short T2 (~9.2µs in the rat brain, compared to ~40ms for bulk water), but it exchanges with 
free water pool. The additive result is that the tissue itself will respond to the CEST technique 
even in the absence of paraCEST agents. This is known as the magnetisation transfer (MT) 
effect, and can also be calculated using the Bloch-McConnell equation. 
The Bloch-McConnell equation takes the form: 
𝑑𝑑𝑡 𝑀!𝑀!𝑀!𝑀! =




Where Li, Kij, 0 are 3x3 matrices representing the physical properties of the corresponding pool; 
[Ma, Mb, Mc, Md]’ are the answers are we are looking for; [M0a, M0b, M0c, M0d]’ are the initial 
state of [Ma, Mb, Mc, Md]’ before CEST begins.  La  , Lb , Lc and Ld are the free water pool, Eu 
proton pool, Yb proton pool, and biomolecule-bound water proton pool respectively. Kab , Kac, and 
Kad are the exchange rates from free water to Eu proton pool, Yb proton pool, and biomolecule-
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bound water proton pool respectively, and Kba , Kca, and Kda are the backward exchange rate 
from the same pools to the free water pool. The exchange directly between the Eu proton pool, 
Yb proton pool, and biomolecule-bound water proton pool are effectively 0. 
Although the details of solving the equation is beyond the scope of thesis, please note that all the 
important physical properties are reported (La, Ld, Kad/ Kda (Stanisz, Odrobina et al. 2005)), or 
measured in our lab using methods previously described (Kab/Kba , Kac/Kca (Dixon, Ren et al. 
2010)), or have little influence on the outcomes of interest and are assumed with reasonable 
values (Lb , Lc (Li, Hudson et al. 2008)). All the RF conditions are set as used for experiments. All 
input values used are given in Appendix 2. The Bloch-McConnell equations are solved between 
±120ppm on 1ppm basis, ±300ppm are solved as a reference for z-spectrum normalization. The 
Mza was collected to form z-spectra as shown in Figure 4.9. All the input parameters and detailed 
form of L, K, 0, M are listed in Appendix 2. 
4.2.7 Middle Cerebral Artery Occlusion (MCAO) Surgery 
Animals used were male Sprague-Dawley rats, kept on a 12 hour light/dark cycle, and given food 
and water ad libitum. Animals arrived at 180-200g and were allowed one week to acclimatize 
before undergoing MCAo surgery at 240-260g. 
An adaptation of the protocol used by Longa et. al. (1989) and Modo et. al. (2000) was used. 
Animals were anesthetized using Isoflurane (4% for induction, 2% for maintenance), and a rostro-
caudal incision was made above the trachea. The right common carotid artery was then exposed, 
and the internal carotid was cleaned until the bifurcation with the pterygopalatine artery was 
visible. The right common carotid was permanently ligated with a suture, and a coated filament 
(Doccol) was inserted through a small incision in the carotid trunk into the internal carotid artery 
and advanced up past the pterygopalatine to the bifurcation with the middle cerebral artery. The 
correct positioning of the filament was judged by distance (~18-20mm) and the feel of resistance, 
at which point it was secured in place and the animal was allowed to recover. After the occlusion 
time of 70min, the animal was re-anesthetized as before and the filament retracted as far as the 
carotid bifurcation, where the tip permanently remained and excess was trimmed off. The wound 
was then sutured and the animal was given IP Buprenex (0.05mg/kg) and topical analgesic cream 
(2.5% Lidocaine, 2.5% Prilocaine, Sandoz) for analgesia, as well as 5ml Plasmalyte IP to help 
with rehydration. Animals were then weighed daily and their wellbeing monitored using basic 
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neurological and distress scales until they regained their pre-op weight (Modo, Stroemer et al. 
2000). Buprenex (0.05mg/kg) was administered every 12 hours for 72 hours following the 
procedure and then as necessary, and both wet and dry food was provided, and intake monitored. 
4.2.8 Stereotactic Injection 
The MCAO model produces animals with very varied lesions (Smith, Stroemer et al. 2011). In 
order to fill the lesion with cells as an approach to tissue engineering, it is necessary to know the 
volume of the lesion (Bible, Chau et al. 2009), and also to remove the extracellular fluid currently 
occupying it so as to achieve homogenous distribution of injected material throughout the cavity 
and avoid unnecessary increases in intracranial pressure during surgery (Massensini, Medberry 
et al. 2014). 
4.2.8.1 Derivation of injection coordinates using MRI 
T2w images (0.156x0.156x0.5mm voxel size) were examined in Jim 6.0 (Xinapse), and a region 
of interest (ROI) was drawn in a damaged slice on the contralateral hemisphere, including 
striatum, cortex and corpus callosum, but avoiding ventricles. The Image was then masked at the 
average intensity of this ROI + 1 standard deviation (Stille, Smith et al. 2013). This allowed clear 
delineation of the hyperintense lesion area. ROIs were then drawn around these hyperintense 
areas, and the lesion volume was calculated .  
The drainage site was selected as the most dorsal point of the lesion, and the injection point as 
the most ventral (Figure 4.5A), and distance between them (AP/L) was required to be at least 
1.5mm to allow for two burr holes in the skull. The MR images were compared with the Allen brain 
atlas to identify Bregma, and the anterior/posterior coordinates of each site were deduced based 
on the number of 0.5mm slices from Bregma to the target slice. Lateral and ventral distances 
were measured in Jim from the midline and dura respectively (Massensini, Medberry et al. 2014). 
4.2.8.2 Injection/drainage procedure 
2-4 weeks after MCAO, animals were anesthetized with Isoflurane (4% for induction, 2% for 
maintenance) and placed in a stereotactic frame (Kopf). A rostro-caudal incision was made to 
expose the skull, and two burr holes were made at the coordinates derived from the animal’s MR 
images (Figure 4.5B). A sterile disposable 23G needle was inserted slowly by hand into the 
drainage site, and the Hamilton needle containing the injectate was inserted into the injection site. 
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The material was then injected using a micro pump (Micro4, WPI) at 5µl/min to a total volume 
equal to the calculated volume of the lesion. Extracellular fluid was observed emerging from the 
drainage needle (Figure 4.5C). 
 
Figure 4.5 Injection/Drainage. Injection and drainage sites are chosen according to the 
topology of the lesion (A). Two burr holes are drilled in the skull (B) and ECF can be 
observed draining from the needle during injection (C). Figure and optimization of 





4.3.1 Agent characteristics 
In order to verify that the two paraCEST agents, Eu-HPDO3A and Yb-HPDO3A (hereafter Eu and 
Yb) could be reliably and separately detected by MRI, solution phantoms were imaged. Complete 
z spectra were acquired for each agent (10mM) from -120 to 120ppm at 0.5ppm intervals to 
ascertain the range of offsets required for detection of each agent. Eu has a single exchange site 
corresponding to a peak at 18ppm, whereas Yb has two exchange sites, corresponding to peaks 
at 69 and 97ppm (Figure 4.6A). 
Images were then acquired with presaturation pulses at the required ppm (16-20 for Eu and 66-71 
and 96-101 for Yb, with 1ppm steps; Reference at 0 and -300ppm) of solutions at different 
concentrations of Eu and Yb agents in PBS, separately and combined. The relationship between 
concentration and asymmetry is linear for both agents, with Yb requiring a higher concentration 
for the same magnitude of contrast. This does not appear to be altered by mixing the agents in 
the same solution (Figure 4.6B). There is some background evident in the 5mM Yb solution at 
18ppm, which is likely due to the presence of unspecific exchange sites on the HPDO3A chelate. 
However, the signal from the Eu solution is much stronger, showing that chelate exchange sites 




Figure 4.6 Agent characteristics in solution. Z spectra of agent solutions showing signal 
intensity compared to the reference at -120ppm, and asymmetry, which is the subtraction 
of the intensity at each chemical shift from it’s corresponding negative (A). MR images of 
solutions at different concentrations at the relevant chemical shifts show a linear 
relationship between concentration and asymmetry (B) 
 
4.3.2 Cell uptake 
The concentration of paraCEST agent required for detection is very high. Gadolinium can be 
detected in the µM range (see Chapter 3), whereas mM concentrations are required for 
paraCEST detection. Therefore, optimising agent uptake with respect to intracellular 
concentration and cell survival is of the utmost importance. Pinocytosis and electroporation have 
both been used to label cells with Gd-HPDO3A, where the most effective method appeared to be 
largely cell type dependent (Di Gregorio, Ferrauto et al. 2013). Neural stem cells (NSCs) and 
endothelial cells (ECs) were each labeled with one paraCEST agent under a variety of pinocytosis 
and electroporation conditions. Since NSCs are generally more susceptible to toxicity than ECs, 
and Eu appears to provide better contrast at lower concentrations, Eu was selected for uptake 
into NSCs, and Yb into ECs. Labeled cells were then harvested and analysed for lanthanide 
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content by inductively coupled plasma mass spectrometry (ICP-MS). The number of cells 
harvested was used as a measure of survival. 
For pinocytosis, agents were dissolved in the cells’ normal growth medium at 50, 100 or 200mM 
and incubated for 12, 24 or 48 hours. For both NSCs and ECs, intracellular agent concentration 
was higher with increasing concentration and incubation time (Figure 4.7A). Cell survival showed 
the opposite response, decreasing with increased concentration and incubation time (Figure 
4.7B). 
For electroporation, an initial range of conditions for testing was determined for each cell type 
using a fluorescent proxy agent, carboxyfluorescein (see section 4.2.3.1). Cells were suspended 
at 3, 6 or 9 million cells/ml in electroporation buffer with agent at 200mM and electroporated. Cell 
uptake and survival was measured as for pinocytosis. For both cell types, using harsher 
electroporation conditions (higher voltage or pulse length) increased agent uptake, although there 
was a larger effect in ECs. Cell density decreased uptake in NSCs, but had no effect on ECs 
(Figure 4.7C). As with pinocytosis, cell survival showed the opposite pattern to cell uptake, with 
harsher conditions resulting in decreased survival in both cell types. Cell density increased 
survival in NSCs, but not ECs (Figure 4.7D). 
It is unclear from these results whether the decreases in cell survival are due to the presence of 
more agent within the cell, or to exposure to toxic conditions during the labeling protocol. If the 
imaging approach is feasible, further experiments will be required to determine effects on survival 
over time, as well as other parameters, such as proliferation and differentiation. Based on these 
data and preliminary imaging experiments shown in Figure 4.2 and Figure 4.8, the conditions 
taken forward were electroporation at 530V, 100µs and 3 x 106 cells per ml (Figure 4.7, purple 
arrows). This gives cell pellets with a concentration of 6.8mM for Eu-NSCs and 9.5mM for Yb-
ECs. The survival shown here when applied to large numbers of cells to produce pellets for 





Figure 4.7 Cell uptake and survival after labeling. With pinocytosis, uptake was increased 
in both cell types by increasing concentration (F=132, p<0.0001 for NSCs and F=101, 
p<0.0001 for ECs) and incubation time (F=72, p<0.0001 for NSCs and F=12, p<0.001 for 
ECs), with a significant interaction between time and concentration (F=20, p<0.0001 for 
NSCs and F=13, p<0.05 for ECs) (A). Survival was decreased in both cell types by 
increasing concentration (F=29, p<0.0001 for NSCs and F=64, p<0.0001 for ECs) and 
incubation time (F=6, p<0.01 for NSCs and F=22, p<0.0001 for ECs), with a significant 
interaction between time and concentration (F=4, p<0.01 for NSCs and F=8, p<0.001 for 
ECs) (B). For electroporation in NSCs, uptake was increased by increasing voltage (F=12, 
p<0.001) and decreased by increasing cell density (F=24, p<0.0001). For ECs, uptake by 
electroporation was increased by increasing pulse length (F=13, p<0.0001), but was not 
affected by cell density (F=0.1, p=0.90) (C). In NSCs, survival after electroporation was 
decreased by increasing voltage (F=259, p<0.0001) but increased by increasing cell 
density (F=55, p<0.0001). For ECs, survival after electroporation was decreased by 
increasing pulse length (F=197, p<0.0001), but was not affected by cell density (F=0.02, 
p=0.98) (D). Purple arrows indicate conditions taken forward. 
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4.3.3 In vitro cell imaging 
The uptake method has previously been shown to affect MRI detection independently of 
concentration due to the intracellular localisation of agent (Di Gregorio, Ferrauto et al. 2013). 
Since ParaCEST agents are highly pH sensitive (Delli Castelli, Terreno et al. 2011), localisation to 
the endosomes and subsequent fusion of the endosomes with low pH lysosomes is likely to 
reduce detection. To assess this in the current experiment, ECs were labeled with Yb via 
pinocytosis and electroporation to give cell pellets with similar intracellular concentrations. Cells 
were labeled by pinocytosis at 100mM incubation concentration for 48h, giving a concentration of 
10.1mM, and via electroporation at 200mM, 530V, 100µs and 3 x 106 cells per ml to give a 
concentration of 9.5mM. These two cell pellet samples were then imaged at 9.4T to compare the 
contrast level for each method.  
Despite having similar concentrations, the cells generated using electroporation gave a stronger 
signal at 97ppm than those generated using pinocytosis (Figure 4.8A). The agents have a strong 
T2 shortening effect, which is greater for cells labeled by pinocytosis than electroporated cells, 
although this is not statistically significant (Figure 4.8B). This does not interfere with agent 
detection, provided a very short TE is used (<10ms), but may interfere with anatomical imaging 
for in vivo applications. Z spectra were generated using image acquisitions at 66-71 and 95-
100ppm at 1ppm per step, with reference images at 0 and -300ppm, with remaining data points 
fitted using smoothing splines (section 4.2.5). Electroporated cells had slightly higher contrast 
than pinocytosis labeled cells at both exchange sites (Figure 4.8C). The site showing the most 




Figure 4.8 MRI detection of cells labeled via pinocytosis or electroporation. Cells labeled 
via electroporation showed a stronger contrast at 97ppm than those labeled via 
pinocytosis (A). The T2 of the cell pellet was much shorter for labeled compared to 
unlabeled cells, and was even shorter for pinocytosis cells than electroporated cells. Data 
is shown as mean ± stdev representing variation within the image (B). The z spectra 
shows increased contrast for electroporated (0.11) compared to pinocytosis (0.083) 
 
4.3.4 Magnetisation Transfer (MT) Effects 
Comparing the shapes of the z spectra in the previous experiments, a clear difference can be 
seen between those acquired in solution (Figure 4.6) and in cells (Figure 4.8). Spectra acquired 
in solution have a narrow water peak at 0ppm with clearly defined peaks associated with each 
agent, whereas in cells the water peak becomes much wider. This is thought to be due to the 
magnetisation transfer (MT) effect. This occurs due to the matrix-like nature of biological 
structures, such as cell membranes, cytoskeletons end extracellular matrix. Excitation of bulk 
water in this scenario can be transferred through large biological molecules to other protons 
slightly off-resonance; thereby causing a widening of the water peak. To assess whether this is 
the cause of the differences observed, the four-pool (free water, Eu, Yb, MT) Bloch-McConnell 
equation was solved numerically in MATLAB using the experimental conditions and tissue 
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properties for the four pools. The agent concentration is set as 10mM. The solution z spectra 
show the asymmetry peaks for the exchange sites at 18ppm for Eu and at 69 and 97ppm for Yb 
(Figure 4.9A). Brain tissue without agent under the detection conditions for each agent shows a 
much wider peak, but no asymmetry as the signal is non-specific. The widening of the peak is 
slightly more apparent for Yb, due to the higher power used (Figure 4.9B). When the agent is 
added to brain tissue, the amount of contrast is reduced. This is much more noticeable for Eu, as 
the exchange site is much closer to water, within the region where MT effects are strongest. For 
Yb, the exchange site at 69ppm is affected more strongly than that at 97ppm, supporting the 
experimental data and showing that 97ppm should be the site to target for in vivo detection 
(Figure 4.9C). 
 
Figure 4.9 Magnetisation Transfer (MT) Effect simulation. Numerical calculation of Bloch-
McConnell equation shows similar z spectra to experimentally acquired data of agent in 
solution (A). MT effects in brain tissue widen the water peak (B), resulting in decreased 
agent contrast (C). 
131 
 
4.3.5 Feasibility of dual population detection 
MT effects result in a large reduction in contrast. Therefore the feasibility of dual population 
detection must be considered. Cell pellets of Eu-NSCs and Yb-ECs were imaged and the amount 
of contrast was determined for each agent in order to predict a cell ratio where both agents could 
be detected. 
Eu-NSCs showed only a very small amount of contrast at 0.011, or 1.1% (Figure 4.10A). Yb-ECs, 
however, showed much better contrast at 97ppm at 1.2 or 12% (Figure 4.10B). Cells were 
therefore mixed at a ratio of 4:1:1 EuNSCs:YbECs:Blank cells. Blank cells were included to allow 
volume for the liquid vehicle that would dilute cells injected in vivo. Imaging of the mixture showed 
that both agents could still be detected, with Eu contrast at 1.1% above blank cells, and Yb 
contrast at 2.4% above blank (Figure 4.10C). Since CEST-MRI is an inherently low-sensitivity 
technique, image averaging is often used to improve contrast (Akansu, Serdijn et al. 2010). 15 
averages were acquired for Eu, and the contrast was increased slightly from 1.1 to 1.2% (Figure 
4.10D). However, the time constraints imposed by cell viability and the long TR required to offset 




Figure 4.10 Cell ratio. Cell pellets were imaged to assess the contrast available from each 
agent, Eu 0.011 (A) and Yb 0.12 (B). Eu-NSCs, Yb-ECs and blank cells were then mixed 
in the ratio 4:1:1, and both cell types were detectable (C). Image averaging was used to 
improve contrast, but only a modest increase could be seen within the time constraints 
(D). 
 
4.3.6 In vivo imaging 
A potential application of paraCEST imaging would be to visualise two cell populations in vivo in 
the context of tissue engineering. Ischemic stroke results in a loss of tissue, leaving a fluid filled 
cyst. Cell therapies have shown promise in stroke, reducing lesion volume and improving motor 
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recovery. However, complete recovery has not been shown, making tissue engineering within the 
cavity an attractive avenue to pursue. NSCs and ECs were implanted directly into the lesion 2-4 
weeks after middle cerebral artery occlusion (MCAO) surgery, and images were acquired the 
following day. 
The first implantation of labeled cells was performed before the problem of MT effects had been 
accounted for. Since Yb at 69ppm appeared to have better contrast (Figure 4.6A), and requires 
lower RF irradiation power, the Yb at 69 ppm was chosen. RF power = 46µT, and RF duration = 
800ms. Cells were labeled by electroporation (200mM, 530V, 100µs), and implanted at a ratio of 
10:6 Yb-ECs:Eu-NSCs at a total density of 200,000 cells/µl. This gives a predicted concentration 
in the lesion of 4.75mM Yb and 2.04mM Eu. Images revealed sufficient contrast to visualise both 
agents within the lesion (Figure 4.11A). However, with the image threshold at the noise level of 
the contralateral hemisphere, it can be seen that rather than a continuous area of contrast, 
individual pixels are visible. This shows that the contrast is at the low limit of detection in 
comparison to background. After optimization of the sequence, unlabeled cells were transplanted 
in order to assess whether differences between the transplant area and contralateral hemisphere 
were sufficient to produce false positive contrast (Figure 4.11B).  
To get a numerical value for contrast, the asymmetry was measured for each voxel within the 
ROIs selected on the T2 images. This was then plotted as mean asymmetry ± standard deviation 
(Figure 4.11C). For the labeled cell transplant, contrast was significantly higher in the transplant 
site compared to the contralateral hemisphere for both agents. The difference for Eu was small 
but significant (p<0.001), with high background at 2.2%, and signal at 2.5%. For Yb, the 
difference was larger at 1.5% signal compared to 0.8% background, reflecting the reduced noise 
at a higher ppm, and increased signal due to the higher concentration. For the unlabeled cell 
transplant, the Eu asymmetry for the transplant site was slightly lower then the contralateral side 
(Signal 1.4%, background 1.5%), but not significantly different (p=0.62). For Yb, signal was -1.0%, 
and background -2.0%. There was a significant difference (p<0.001) here, showing that the 
differences between the lesion transplant and healthy tissue are sufficient to produce a false 
positive Yb contrast. This is due to MT asymmetry, and the difference in the biomolecule bound 
proton pool between healthy tissue and newly transplanted cells, which are in suspension without 
extracellular matrix. This could potentially be improved by transplanting cells within an ECM 




Figure 4.11 In vivo images acquired 1 day after transplantation into the stroke lesion of 
either labeled (A) or unlabeled cells (B). The mean contrast for each ROI was plotted as 
mean ±  stdev and t tests were used to compare transplant site with the contralateral 
hemisphere. For labeled cells, contrast was significantly higher in the transplant site for 
both Eu (p<0.001) and Yb (p<0.001). For unlabeled cells, contrast was not significantly 




ParaCEST MRI offers exciting possibilities for tracking multiple cell populations over time, which 
is becoming an increasingly important consideration for tissue engineering applications. We here 
tested the potential of two paraCEST agents, Eu-HPDO3A and Yb-HPDO3A, for cell identification 
in a stroke model. Agents could be detected independently in solution, but their detection when 
inside cells was hampered by magnetization transfer (MT) effects. In vivo, Eu labeled cells could 
be detected, but at the RF power required for Yb, the MT asymmetry in healthy tissue was high, 
masking differences due to cell labeling.  
4.4.1 Limitations of methodology 
Due to the technical challenges, this project was much more time consuming than expected. As a 
result, the methodology leaves much to be desired. Firstly, the final in vivo images were obtained 
from only one rat in each group. Particularly given the small effect size and the high level of 
unspecific signal from MT asymmetry, replicates would be required to confirm the result that Eu- 
(but not Yb-)labeled cells can be reliably detected in vivo. Cell pellet experiments were also n=1 
for each specific comparison, but these results taken together with optimisation experiments 
provide some level of confidence that cell pellet detection is reliable for both agents. However, 
further replicates would of course still be desirable. 
The other major issue relates to biological relevance. Due to the low sensitivity of paraCEST, the 
cell mixture injected was based on maximising the concentration of both agents rather than the 
most promising biological paradigm. Cells were injected at 200,000 cells/µl, which is much more 
dense than the host brain tissue, but allowed for a higher agent concentration. The NSC:EC ratio 
was also adjusted based on optimal imaging conditions rather than optimal biology for tissue 
formation. However, this study was designed to explore the suitability of these agents for imaging 
these two cell populations, rather than to examine the biological processes. If further work were to 
be done on this project with an improved agent design, these aspects would need to be taken into 
account, as well as a more thorough assessment of the functionality of labeled cells. The 
electroporation process decreased cell survival and it is therefore likely that there were 
detrimental effects on surviving cells that were not picked up with the assay undertaken here. A 
more thorough characterisation should include differentiation of NSCs as well as a matrigel tube 
formation assay for ECs and long term survival for both cell types.  
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4.4.2 Challenges in paraCEST imaging 
The major challenge encountered here was MT effects, of which there are two aspects. Firstly, 
conventional MT refers to the widening of the water peak, as shown in Figure 4.9, whereby 
magnetisation is transferred through large biological molecules, reducing the specificity of 
excitation. The second type is MT asymmetry, which is thought to arise from a shift difference 
between the solid-like macromolecular chemical shift centre and bulk water resonance (Hua, 
Jones et al. 2007), and is likely responsible for the negative asymmetry values seen in Yb 
background in vivo. These cause a reduction in contrast compared to the same concentration in 
solution, and further exacerbate the problem of a high detection threshold. Increasing the power 
of the saturation pulse can increase contrast, but also increases MT effects, in addition to sample 
heating. Improving intracellular concentration or the CEST properties of the agents are therefore 
attractive options to improve detection. We have shown here that intracellular concentration can 
be increased, but that it comes at a high cost of cell survival. The electroporation conditions used 
for imaging gave 1.6-2.2 x 106 Ln/cell, which is similar to that achieved by others using Gd in the 
same chelate (Di Gregorio, Ferrauto et al. 2013). It is therefore evident that a change in the agent 
would be required to further increase uptake, such as conjugation to nanoparticles. This may also 
provide opportunities to manipulate the chemistry, such that the exchange rate could be 
optimised, which would further improve contrast (Siriwardena-Mahanama and Allen 2013). 
However, altering the exchange rate appears to be less straightforward for paraCEST agents than 
traditional MR contrast agents. A recent study aimed to conjugate EuDOTA-(gly)4 to silica 
nanoparticles to reduce the exchange rate, but found instead that the signal was quenched by 
excess amino protons on the particle surface (Evbuomwan, Merritt et al. 2012). It seems therefore 
that significant advances are required before uptake and exchange rate can be improved in this 
manner, and that suitable materials must be chosen with the utmost care.  
A recent publication shows a related technique of highly shifted proton MR imaging (Schmidt, 
Nippe et al. 2014), where lanthanide based agents with a large chemical shift are directly 
detected using attached methyl groups. This technique potentially has much improved sensitivity, 
with in vitro detection at 25µM, compared to ~2mM required here for paraCEST, and may 
therefore be a more promising avenue for this application. However, there is additional equipment 
required for imaging, which may hamper any clinical translation. 
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4.4.3 Alternative uses of CEST 
An alternative approach to cell tracking is the use of a CEST reporter gene. By over-expressing 
hPRM1, Bar-Shir, Liu et al. (2014) could detect HEK293 cells in a 3D culture system. When 
compared to wild type cells, the difference in contrast was ~0.2%, similar to the contrast achieved 
here with Eu. However, the chemical shift of hPRM1 is 1.5ppm, meaning that a very low power of 
3.6µT can be used. This potentially reduces heating effects and may therefore allow the use of a 
much shorter TR, which could significantly reduce scanning time, or allow more averages to be 
obtained. They note, however, that this was only in vitro, and contrast in vivo may be somewhat 
different. 
Tissue engineering poses unique challenges to the imaging field, and CEST MRI may have other 
applications besides cell tracking. Vascularization of the graft is a key process, and targeted 
lipoCEST may be one way to image this. Flament, Geffroy et al. (2013) used intravenous RGD-
lipoCEST to target αυβ3 integrin, which is upregulated during tumour vascularisation. Using this 
approach, they were able to visualise increased contrast in the tumour compared to the 
contralateral hemisphere. However, the expression level of angiogenesis markers in transplants 
has not been widely assessed and the levels may be significantly lower than tumorigenesis. 
Attempts to use molecular MRI to visualise post-stroke increases in PECAM-1 expression using 








We here assessed the potential of paraCEST for detection of multiple cell populations. The 
agents Eu-HPDO3A and Yb-HPDO3A can be selectively detected in solution, and can label calls 
via pinocytosis or electroporation. When separate populations of cells are labeled with the two 
agents, these can be selectively detected in vitro. However, the presence of MT effects reduce 
the contrast compared to detection in solution. In vivo, MT asymmetry is an even larger problem, 
as the difference between newly transplanted cells and healthy tissue including extracellular 
matrix is large enough to generate false positive contrast at the high RF power required for Yb 
detection. At the lower power required for detection of Eu-labeled cells however, a small but 
significant difference was observed compared to unlabeled transplant. This demonstrates that 
paraCEST imaging of multiple populations does have potential, but further replicates would be 
required to verify this, and significant changes in agent chemistry are required before they 





Chapter 5: Discussion  . 
In this thesis, current and novel methods for identifying transplanted cells have been assessed. 
As transplants become more sophisticated, the demands on identification methods increase. We 
have here shown some of the strengths of current methods, as well as their limitations for more 
complex environments. 
5.1 Exogenous labels for identification of transplanted cells 
Exogenous labels refers to labels added to a population of cells prior to transplantation, and 
applies both to histological labels, such as Hoechst and PKH26, and also to those used for in vivo 
imaging methods, such as iron oxide and gadolinium labels for MRI. 
The primary concern with exogenous labels is their potential for errant labeling of host cells. This 
problem has been demonstrated for Hoechst (Iwashita, Crang et al. 2000), where Hoechst was 
found both to label a region of host cells surrounding the graft, and to persist after transplanted 
cells were no longer present. BrdU was considered more reliable in this respect due to its cellular 
incorporation only occurring during DNA synthesis and it being permanently integrated into DNA. 
However, in the injured brain, DNA synthesis is occurring during damage repair, as well as gliosis. 
Consequently, BrdU has been shown in host cells after transplantation of live cells, dead cells or 
label alone (Burns, Ortiz-Gonzalez et al. 2006). It is therefore clear that these labels are taken up 
by host cells, and that the presence of free label must be minimized. This problem becomes 
exacerbated in the context of MRI, where Gd-based labels in solution have a larger effect on 
relaxivity than labels within cells (Kok, Hak et al. 2009).  
By allowing 24 hours between completion of labeling and cell transplantation, as recommended 
by Lassailly, Griessinger et al. (2010), we here showed very little leakage of exogenous labels 
(i.e. false positive) for BrdU, PKH26, and Qtracker in vivo. What was observed instead was a 
significant number of false negatives, where transplanted cells were negative for the exogenous 
label. This highlights the difficulties in relying on previously published data to select a label for a 
specific application. The labeling protocol, cell type and in vivo model are all likely to have 
significant effects on label reliability. 
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Cell survival after transplantation currently remains low, meaning that the majority of transplanted 
cells will die (Smith, Stroemer et al. 2011). The eventual fate of a label after cell death requires 
investigation, as has been demonstrated by transplantation of SPIO labeled cells in immune 
competent and immune deficient mice, where signal was shown to persist more strongly in 
immune-competent mice where the transplant was rejected and cells died (Berman, 
Galpoththawela et al. 2011). The use of reporter genes, such as ferritin, have been shown to 
overcome this problem (Naumova, Balu et al. 2014). However, for Gadolinium this may not be an 
issue since the chelated molecule is smaller and able to diffuse away from the graft site more 
easily upon cell death (Guenoun, Ruggiero et al. 2013). This was corroborated by the data shown 
here, where GdAuNP MR contrast was no longer visible after cell death. 
5.2 Challenges in cell tracking 
The primary challenge in cell tracking remains that of the observer effect, where the attempt to 
observe the behaviour of the cells by applying labels can alter that behaviour. Some studies still 
rely solely on cell toxicity and proliferation tests to assess the suitability of a tracking method. 
However, measuring long-term survival and phenotypic effects are vital in order to avoid affecting 
the therapeutic efficacy of a graft. Our work showed that even commonly used histological labels 
showing no acute effect on cell viability can have significant effects on cell survival even one 
week later. Extending this measure to a three week differentiation protocol as used by El 
Akabawy, Martinez-Medina et al. (2011) would allow us to ascertain whether the phenotypic 
effects can be negated by the use of small molecules to direct differentiation, or whether the 
differences are magnified by the longer time course.  
In order to take any cell tracking method forward for use in a therapeutic efficacy study, the 
predicted therapeutic mechanism of the implant should be taken into consideration. For studies 
aiming to achieve integration and long-term survival of grafted cells, assessment should be 
extended to include synapse formation and generation of action potentials (Sekar, Kizana et al. 
2007).  
However, in vitro models cannot accurately model all the environmental conditions that cells may 
encounter in vivo and as such, unexpected effects may still occur even after rigorous testing. The 
inclusion of an unlabeled cell control therefore unfortunately remains necessary to establish the 
absence of label effects (Modo, Beech et al. 2009). This  begins to erode the utility of cell labeling, 
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as the workload is essentially doubled for each study with a new label, and thereafter every time 
the cell line, label or animal model is altered. Finding endogenous markers of transplanted cells 
therefore becomes much more appealing. However, this is much easier for histological labels 
than for MRI. Histology’s high resolution allows it to take advantage of small differences, such as 
cell gender, as the presence of a Y chromosome can be visualised using in situ hybridisation 
(ISH) (Hruban, Long et al. 1993). The use of cell type specific proteins, however, should be 
undertaken with care. In the context of regenerative medicine, significant changes in transplanted 
cells are expected and as such a marker labeling the whole population in vitro may not 
necessarily be as reliable over time in vivo. 
Cell tracking in vivo has additional challenges to overcome. Particularly for the brain, the 
presence of the skull means that non-invasive cell visualisation must rely on modalities with much 
lower sensitivity and resolution. The careful design of contrast agents can provide great 
improvements. The GdAuNP agent used here was designed specifically for good cell uptake and 
compatibility, and use at high field after feedback from experiments with GRID (Brekke, Morgan et 
al. 2007, Modo, Beech et al. 2009), and showed potential for reliable cell identification. The 
paraCEST agents are somewhat newer and have not been optimised for this system, and our 
experiments showed that they are not yet reliable. However, the data generated here can be used 
to inform improved design of the next generation of agent. 
5.3 Imaging tissue engineering 
Although tracking individual transplant components can provide valuable data, there are other 
parameters to consider in tissue engineering. An additional challenge is to indicate if implanted 
cells have generated an appropriate type of tissue. Establishing if a tissue is developing is 
significantly more challenging than establishing if implanted cells have differentiated into one 
appropriate neuronal phenotype, which can be achieved using MRS (Chung, El Akabawy et al. 
2013). The primary question is whether a tissue has developed with appropriate diffusion barriers 
(e.g. ECM, axons), as these are essential to keep the tissue together. Their presence can be 
visualised using diffusion-weighted MRI (Bible, Dell'acqua et al. 2012). However, diffusion barriers 
also limit the flow of extracellular fluid typically found inside the lesion cavity, potentially reducing 
the supply of nutrients to grafted tissue. It is therefore important to ensure delivery of nutrients 
and oxygen to the de novo tissue by angiogenesis, as well as arteriogenesis. Monitoring the 
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emergence of an appropriate blood supply to this area is consequently crucial for its long-term 
survival (Boehm-Sturm, Farr et al. 2013). Perfusion MRI can demonstrate appropriate flow of 
blood to the area, whereas MR angiography can visualize the presence of major blood vessels 
(Seevinck, Deddens et al. 2010). However, all these aspects are also present in tumours and 
therefore the site-appropriateness of the de novo tissue also requires interrogation. 
Replacing lost striatal tissue with a new tissue that has the biochemical properties of the original 
tissue does not necessarily translate into recovery, as cells must also integrate into neural 
networks of the host brain. Glial scarring and the lack of appropriate axonal connections can 
potentially form a tissue that is not connected. Therefore appropriate in vivo methods need to be 
developed to establish if the newly formed tissue is responsive to input from the host brain and 
vice versa that the regrown striatum can indeed elicit activity in the host brain. Pharmacological 
MRI is one means to investigate if the new striatum is specifically responsive to agents that 
stimulate striatal neuron activity (Chen, Brownell et al. 1999, Roberts, Price et al. 2007). After fetal 
tissue transplants, functional MRI has, for instance, also been used to demonstrate the integration 
of the new tissue with host activity (Bluml, Kopyov et al. 1999). It is also conceivable that if a new 
tissue is integrated with the brain it will fire spontaneously and in the absence of a regulatory 
feedback can be the focal point for epileptic discharges. Electroencephalography (EEG) can help 
to establish if inappropriate discharges are indeed occurring, in the absence of behavioural 
manifestations. Appropriate monitoring of the functional integration of cells will also be important 
to ensure the safety of this approach. 
Although the connections between new and existing tissue are thought to be essential to provide 
an integration into networks that produce behaviour, merely establishing physical synaptic 
connections is unlikely to be sufficient to ensure that this new tissue is indeed functionally 
integrated (Hicks, Hewlett et al. 2007). As during development, these new neurons are likely to be 
a “blank slate” and they will require functional activity from other cells to establish and maintain a 
functional integration (Dobrossy, Busse et al. 2010). Rehabilitative training specifically geared 
towards integrating these newly established cells and connections is likely to be a major 
requirement to ensure the efficacy of this approach. It is likely that the rehabilitative needs of this 
tissue are very different from those currently employed to promote recovery after stroke. 
Rehabilitation after stroke is geared towards promoting plasticity in remaining brain regions, but is 
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not necessarily appropriate to train a new tissue or guarantee its integration with other brain 
regions. Therefore significant challenges remain ahead. 
 
In summary, we here highlight some of the issues that remain even when using simple 
histological dyes to identify transplanted cells, and recommend diligent assessment of their 
cellular effects and reliability before use. The results shown here and elsewhere demonstrate the 
high variability in reliability between labels, cell types, labeling protocols and in vivo models, and 
demonstrate the need for highly individualised assessment of cell labeling for each proposed 
application. We also introduce GdAuNPs as an MRI contrast agent providing highly specific cell 
detection on T1 weighted images without interfering with T2 weighted anatomical imaging, 
demonstrating a significant improvement compared to previous Gd labels, although its utility in 
tracking over time remains to be assessed. Finally, we introduce paraCEST as a technique with 
the potential to image multiple transplant components for tissue engineering. However, we here 
show that there are issues with background signal, and that significant improvements are required 
before this technique becomes applicable to tissue engineering. In the context of regenerative 
medicine and increasingly complex transplants, it seems that labeling transplant components 
comes with a high cost in terms of cellular effects, and therefore potentially therapeutic efficacy, 
whereas monitoring tissue formation and graft activity are potentially free of this cost. Future study 
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Appendix 2: Parameters and matrix forms of the Bloch-
McConnell equation 
The Bloch-McConnell  equation takes the form: 
𝑑𝑑𝑡 𝑀!𝑀!𝑀!𝑀! =





− 1𝑇!! −∆𝜔! 0+∆𝜔! − 1𝑇!! +𝜔!0 −𝜔! − 1𝑇!!
 
𝐾!" = 𝑘!" 0 00 𝑘!" 00 0 𝑘!"  
𝟎 = 0 0 00 0 00 0 0  
𝑀! = 𝑀!"𝑀!"𝑀!"  
𝑀!! = 00𝑝!  is the initial state of Mi. 
 Here T1i, T2i are relaxation parameters of each pool; ∆ωi is saturation offsets of each pool; ωi is 
RF amplitude; kij is the exchange rate from pool i to pool j; pi is the ratio of each pool, and pa + pb 






Table of parameters, showing all input values used: 
 Water pool: Free Biol. Mol Eu 18ppm Yb 69ppm Yb 97ppm 
T1 (s) 1.4 0.1 0.77 0.77 0.77 
T2 (s) 0.04 0.0000092 0.033 0.033 0.033 
Δωi (offset, ppm) 0 0 18 69 97 
Ratio 0.92 0.08 0.0001 0.0001 0.0001 
k to free water  
(measured, s-1) - 50 5,000 10,000 15,000 
k from free water 
 (calculated, s-1) - 4.35 0.54 1.09 1.63 
RF power (µT) - - 28 48 48 
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